Biotech Showcase 2015 EBD Group Demy-Colton Image Map
Share:
Email this page Share this on LinkedIn Share this on Twitter

Biotech Showcase™ 2015 Presenting Companies

Click on any row to see more company information

Abzena Group
Abzena Group
(AIM:ABZA)
Cambridge, United Kingdom
Abzena provides a suite of services and technologies that enable the development of better biopharmaceuticals. Its service operations provide a growing revenue stream, and it ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Abzena Group

Abzena Group is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:30 am. Room Mission II.
Abzena Group
Track: C
City: Cambridge
Country: United Kingdom
Ownership: PUBLIC
Ticker: ABZA
Stock exchange: AIM
Abzena provides a suite of services and technologies that enable the development of better biopharmaceuticals. Its service operations provide a growing revenue stream, and it sees the potential for additional revenue through royalty bearing licenses for the application of its technology by partners.
Connect with Abzena Group on partnering360®

Biotech Showcase™ 2015
ACEA Biosciences
ACEA Biosciences
San Diego, California, United States
ACEA Biosciences is a development stage biotechnology company with an emphasis on oncology and inflammation. The company’s pipeline includes 4 pre-clinical and clini...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ACEA Biosciences

ACEA Biosciences is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:00 am. Room Mission I.
ACEA Biosciences
Track: B
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
ACEA Biosciences is a development stage biotechnology company with an emphasis on oncology and inflammation. The company’s pipeline includes 4 pre-clinical and clinical stage assets.

Visit: http://www.aceabio.com
Connect with ACEA Biosciences on partnering360®

Biotech Showcase™ 2015
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
(NYSE-M:ATNM)
New York, New York, United States
Actinium is developing targeted payload immunotherapeutics for the treatment of advanced cancers. Its targeted radiotheraphy is based on its delivery platform for the ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 10:00 am. Room Powell.
Actinium Pharmaceuticals, Inc.
Track: D
City: New York
State: New York
Country: United States
Ownership: PUBLIC
Ticker: ATNM
Stock exchange: NYSE-M
Actinium is developing targeted payload immunotherapeutics for the treatment of advanced cancers. Its targeted radiotheraphy is based on its delivery platform for the therapeutic use of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharamceuticals in conjunction with monoclonal antibodies.

Visit: http://www.actiniumpharma.com
Connect with Actinium Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2015
Adaptimmune
Adaptimmune
Abingdon, United Kingdom
Adaptimmune is a clinical stage cell therapy company targeting cancer. It has multiple clinincal trials of its engineered TCR T-cell underway in the US.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Adaptimmune

Adaptimmune is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 11:45 am. Room Mission I.
Adaptimmune
Track: B
City: Abingdon
Country: United Kingdom
Ownership: PRIVATE
Adaptimmune is a clinical stage cell therapy company targeting cancer. It has multiple clinincal trials of its engineered TCR T-cell underway in the US.

Visit: http://www.adaptimmune.com
Connect with Adaptimmune on partnering360®

Biotech Showcase™ 2015
Admedus
Admedus
(ASX:AHZ)
Minneapolis, Minnesota, United States
Admedus invests in and develops next generation technologies. Its lead regenerative tissue product, CardioCel, is on the market in the US and Europe. The company has diversifi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Admedus

Admedus is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 5:00 pm. Room Mission I.
Admedus
Track: B
City: Minneapolis
State: Minnesota
Country: United States
Ownership: PUBLIC
Ticker: AHZ
Stock exchange: ASX
Admedus invests in and develops next generation technologies. Its lead regenerative tissue product, CardioCel, is on the market in the US and Europe. The company has diversified assets that range from those in R&D to marketed products.

Visit: http://www.admedus.com
Connect with Admedus on partnering360®

Biotech Showcase™ 2015
Advanced Inhalation Therapies
Advanced Inhalation Therapies
Rehovot, Israel
This Phase 2 biopharmaceutical company develops Nitric Oxide formulations to treat various respiratory diseases. It has completed a successful Phase 2a trial for RSV and Cysti...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Advanced Inhalation Therapies

Advanced Inhalation Therapies is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 11:45 am. Room Hearst.
Advanced Inhalation Therapies
Track: A
City: Rehovot
Country: Israel
Ownership: PRIVATE
This Phase 2 biopharmaceutical company develops Nitric Oxide formulations to treat various respiratory diseases. It has completed a successful Phase 2a trial for RSV and Cystic Fibrosis and plans to complete Phase 2b this winter and initiate Phase 3 trials late in 2015.

Visit: http://www.ait-pharm.com
Connect with Advanced Inhalation Therapies on partnering360®

Biotech Showcase™ 2015
Aeterna Zentaris
Aeterna Zentaris
(NASDAQ:AEZS)
Québec, Quebec, Canada
Aeterna Zentaris a specialty biopharmaceutical company developing and commericializing treatments in concology and endocrinology. Its lead clinical program is a Phase 3 trial ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aeterna Zentaris

Aeterna Zentaris is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 3:30 pm. Room Mission II.
Aeterna Zentaris
Track: C
City: Québec
State: Quebec
Country: Canada
Ownership: PUBLIC
Ticker: AEZS
Stock exchange: NASDAQ
Aeterna Zentaris a specialty biopharmaceutical company developing and commericializing treatments in concology and endocrinology. Its lead clinical program is a Phase 3 trial in endometrial cancer. The company has also started a commercial program with the co-promotion of an estrogen replacement therapy in some specific US territories.

Visit: http://www.aezsinc.com
Connect with Aeterna Zentaris on partnering360®

Biotech Showcase™ 2015
Aethlon Medical, Inc.
Aethlon Medical, Inc.
(OTC:AEMD)
San Diego, California, United States
Aethlon Medical is a clinical stage company with a first-in-class device that selectively targets the rapid elimination of circulating viruses including Ebola, Hep C and HIV. ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aethlon Medical, Inc.

Aethlon Medical, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 4:00 pm. Room Mission I.
Aethlon Medical, Inc.
Track: B
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: AEMD
Stock exchange: OTC
Aethlon Medical is a clinical stage company with a first-in-class device that selectively targets the rapid elimination of circulating viruses including Ebola, Hep C and HIV. It also targets tumor-secretive exosomes that promote cancer progression.

Visit: http://www.aethlonmedical.com
Connect with Aethlon Medical, Inc. on partnering360®

Biotech Showcase™ 2015
AgeneBio, Inc.
AgeneBio, Inc.
Baltimore, Maryland, United States
AgeneBio is a clinical stage pharmaceutical company with a Phase 3 ready product that may slow the progression or delay the onset of Alzheimer’s dementia. It also has a smal...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AgeneBio, Inc.

AgeneBio, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 9:00 am. Room Hearst.
AgeneBio, Inc.
Track: A
City: Baltimore
State: Maryland
Country: United States
Ownership: PRIVATE
AgeneBio is a clinical stage pharmaceutical company with a Phase 3 ready product that may slow the progression or delay the onset of Alzheimer’s dementia. It also has a small molecule program targeting unmet needs in CNS diseases including aMCI, autism and schizophrenia.

Visit: http://www.agenebio.com
Connect with AgeneBio, Inc. on partnering360®

Biotech Showcase™ 2015
Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings, Inc.
(OTCQB:AMBS)
San Francisco, California, United States
Amarantus Bioscience is a clinical stage biotechnology company that discovers and develops treatments and diagnostics for neurodegenerative diseases. The company has a Phase 2...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 3:30 pm. Room Mission I.
Amarantus Bioscience Holdings, Inc.
Track: B
City: San Francisco
State: California
Country: United States
Ownership: PUBLIC
Ticker: AMBS
Stock exchange: OTCQB
Amarantus Bioscience is a clinical stage biotechnology company that discovers and develops treatments and diagnostics for neurodegenerative diseases. The company has a Phase 2b ready asset for Parkinson’s levodopa induced dyskinesia and has an exclusive license to the Lymphocyte Proliferation test.

Visit: http://www.amarantus.com/
Connect with Amarantus Bioscience Holdings, Inc. on partnering360®

Biotech Showcase™ 2015
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
(OTCQX:AVXL)
New York, New York, United States
Anavex is a clinical-stage biopharmaceutical company focused on the discovery of drug candidates to treat Alzheimer’s disease, other CNS diseases and various types of cancer...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 2:00 pm. Room Mission I.
Anavex Life Sciences Corp.
Track: B
City: New York
State: New York
Country: United States
Ownership: PUBLIC
Ticker: AVXL
Stock exchange: OTCQX
Anavex is a clinical-stage biopharmaceutical company focused on the discovery of drug candidates to treat Alzheimer’s disease, other CNS diseases and various types of cancer. Its lead product for Alzheimer’s is now in Phase 2 clinical trial.

Visit: http://www.anavex.com
Connect with Anavex Life Sciences Corp. on partnering360®

Biotech Showcase™ 2015
ANERGIS SA
ANERGIS SA
Epalinges, Switzerland
Anergis is a clinical stage company developing proprietary allergy vaccines that would require only 2 months of treatment. The clinical efficacy and disease modifying potentia...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ANERGIS SA

ANERGIS SA is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:30 am. Room Hearst.
ANERGIS SA
Track: A
City: Epalinges
Country: Switzerland
Ownership: PRIVATE
Anergis is a clinical stage company developing proprietary allergy vaccines that would require only 2 months of treatment. The clinical efficacy and disease modifying potential of its lead candidate has been confirmed over two natural birch pollen seasons in 240 patients.

Visit: http://www.anergis.ch
Connect with ANERGIS SA on partnering360®

Biotech Showcase™ 2015
ANEW Oncology, Inc.
Phoenix, Arizona , United States
Anew Oncology is a private company founded in 2014 and preparing in 2015 to begin Phase III studies of biologic drugs with known mechanisms and large markets. A proprietary EP...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ANEW Oncology, Inc.

ANEW Oncology, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:45 am. Room Hearst.
Track: A
City: Phoenix
State: Arizona
Country: United States
Ownership: PRIVATE
Anew Oncology is a private company founded in 2014 and preparing in 2015 to begin Phase III studies of biologic drugs with known mechanisms and large markets. A proprietary EPO will start Phase III in 2015 and the Company has three Mabs with Phase II efficacy and safety data that will be developed either as full BLAs or as “biosimilars” in our North American and European target markets.

Visit: http://anew-oncology.com/home.html

Biotech Showcase™ 2015
Antisense Therapeutics Ltd
Antisense Therapeutics Ltd
(ASX:ANP)
Toorak, Victoria, Australia
Antisense Therapeutics is developing an advanced stage pipeline of second-generation antisense drugs. Its lead compounds are in Phase 2 clinical development with near-term mil...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Antisense Therapeutics Ltd

Antisense Therapeutics Ltd is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 4:00 pm. Room Mission I.
Antisense Therapeutics Ltd
Track: B
City: Toorak
State: Victoria
Country: Australia
Ownership: PUBLIC
Ticker: ANP
Stock exchange: ASX
Antisense Therapeutics is developing an advanced stage pipeline of second-generation antisense drugs. Its lead compounds are in Phase 2 clinical development with near-term milestones acting on validated targets in acromegaly and multiple sclerosis. It has a partnership and worldwide licensing agreement with Isis Pharmaceuticals.
Connect with Antisense Therapeutics Ltd on partnering360®

Biotech Showcase™ 2015
Aperiomics
Ashburn, Virginia, United States
Aperiomics is a commercial stage company with an infectious disease diagnostic test based on bioinformatics.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aperiomics

Aperiomics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 8:30 am. Room Mission I.
Track: B
City: Ashburn
State: Virginia
Country: United States
Ownership: PRIVATE
Aperiomics is a commercial stage company with an infectious disease diagnostic test based on bioinformatics.

Visit: http://www.aperiomics.com
Connect with Aperiomics on partnering360®

Biotech Showcase™ 2015
Apogenix GmbH
Apogenix GmbH
Heidelberg, Germany
Agogenix develops protein therapeutics for the treatment of diseases such as cancer by targeting pathways involved in growth, migration and apoptosis of diseased cells. Its mo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Apogenix GmbH

Apogenix GmbH is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 4:15 pm. Room Hearst.
Apogenix GmbH
Track: A
City: Heidelberg
Country: Germany
Ownership: PRIVATE
Agogenix develops protein therapeutics for the treatment of diseases such as cancer by targeting pathways involved in growth, migration and apoptosis of diseased cells. Its most advanced product has successfully a controlled completed Phase 2 proof-of-concept study for the treatment of brain tumors.

Visit: http://www.apogenix.com
Connect with Apogenix GmbH on partnering360®

Biotech Showcase™ 2015
Apricus Biosciences Inc
Apricus Biosciences Inc
(NASDAQ:APRI)
San Diego, California, United States
This company’s lead product is approved for the treatment of erectile dysfunction in Europe and Canada and will be commercialized by its marketing partners. Its second-gener...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Apricus Biosciences Inc

Apricus Biosciences Inc is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 3:30 pm. Room Mission I.
Apricus Biosciences Inc
Track: B
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: APRI
Stock exchange: NASDAQ
This company’s lead product is approved for the treatment of erectile dysfunction in Europe and Canada and will be commercialized by its marketing partners. Its second-generation of the device is under development. It has also recent initiated a Phase 2a trial for a product for the treatment of Raynaud’s phenomenon.

Visit: http://www.apricusbio.com
Connect with Apricus Biosciences Inc on partnering360®

Biotech Showcase™ 2015
Aptose Biosciences Inc.
Aptose Biosciences Inc.
(NASDAQ:APTO)
Toronto, Ontario, Canada
This clinical stage biotechnology company has a lead program that has completed a Phase 1 study in patients with solid tumors. It recently received IND allowance from the FDA ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aptose Biosciences Inc.

Aptose Biosciences Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 4:00 pm. Room Powell.
Aptose Biosciences Inc.
Track: D
City: Toronto
State: Ontario
Country: Canada
Ownership: PUBLIC
Ticker: APTO
Stock exchange: NASDAQ
This clinical stage biotechnology company has a lead program that has completed a Phase 1 study in patients with solid tumors. It recently received IND allowance from the FDA to initiate a Phase 1b study in patients with relapsed/ refractory blood cancers including AML, high-risk MDA, lymphomas and multiple myeloma.

Visit: http://www.aptose.com
Connect with Aptose Biosciences Inc. on partnering360®

Biotech Showcase™ 2015
Aradigm Corporation
Aradigm Corporation
(NASDAQ:ARDM)
Hayward, California, United States
Aradigm is a clincial stage company targeting respriatory diseases and infections. Its lead program is in Phase 3 trials in bronchiectasis patients. The company may pursue add...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aradigm Corporation

Aradigm Corporation is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 2:30 pm. Room Powell.
Aradigm Corporation
Track: D
City: Hayward
State: California
Country: United States
Ownership: PUBLIC
Ticker: ARDM
Stock exchange: NASDAQ
Aradigm is a clincial stage company targeting respriatory diseases and infections. Its lead program is in Phase 3 trials in bronchiectasis patients. The company may pursue additional indications for its lead candidate including cystic fibrosis, non-TB mycobacterial lung infections and biodefense applications.

Visit: http://www.aradigm.com
Connect with Aradigm Corporation on partnering360®

Biotech Showcase™ 2015
Arch Therapeutics (ARTH)
Arch Therapeutics (ARTH)
(OTCBB:ARTH)
Wellesley, Massachusetts, United States
Arch Therapeutics is a pre-clinical medical device company with an innovative approach to the rapid cessation of bleeding and control of fluid leakage during surgery and traum...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Arch Therapeutics (ARTH)

Arch Therapeutics (ARTH) is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:00 am. Room Mission II.
Arch Therapeutics (ARTH)
Track: C
City: Wellesley
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: ARTH
Stock exchange: OTCBB
Arch Therapeutics is a pre-clinical medical device company with an innovative approach to the rapid cessation of bleeding and control of fluid leakage during surgery and trauma care. The underlying technology supports a platform of smart materials that address a specialized field that it calls ‘statis and barrier applications.’

Visit: http://www.archtherapeutics.com
Connect with Arch Therapeutics (ARTH) on partnering360®

Biotech Showcase™ 2015
Arcturus Therapeutics
Arcturus Therapeutics
San Diego, California, United States
Arcturus is a pre-clinical company targeting rare diseases.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Arcturus Therapeutics

Arcturus Therapeutics is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 8:15 am. Room Hearst.
Arcturus Therapeutics
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Biotech Showcase™ 2015
ARGEN-X NV
ARGEN-X NV
(EURONEXT:ARGX)
AH BREDA, Netherlands
arGEN-X is a clinical-stage biopharmaceutical company that creates and develops differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune disease...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ARGEN-X NV

ARGEN-X NV is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 2:30 pm. Room Powell.
ARGEN-X NV
Track: D
City: AH BREDA
Country: Netherlands
Ownership: PUBLIC
Ticker: ARGX
Stock exchange: EURONEXT
arGEN-X is a clinical-stage biopharmaceutical company that creates and develops differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. It has generated a pipeline of differentiated antibody candidates through its discovery platform.

Visit: http://www.argen-x.com
Connect with ARGEN-X NV on partnering360®

Biotech Showcase™ 2015
Argos Therapeutics
Argos Therapeutics
(NASDAQ:ARGS)
Durham, North Carolina, United States
Argos Therapeutics is a biopharmaceutical company that develops and commercializes fully personal immunotherapies for the treatment of cancer and infectious disease. Its most ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Argos Therapeutics

Argos Therapeutics is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 2:30 pm. Room Powell.
Argos Therapeutics
Track: D
City: Durham
State: North Carolina
Country: United States
Ownership: PUBLIC
Ticker: ARGS
Stock exchange: NASDAQ
Argos Therapeutics is a biopharmaceutical company that develops and commercializes fully personal immunotherapies for the treatment of cancer and infectious disease. Its most advanced candidate is being evaluated in a pivotal Phase 3 trial for the treatment of metastatic renal cell carcinoma.

Visit: http://www.argostherapeutics.com
Connect with Argos Therapeutics on partnering360®

Biotech Showcase™ 2015
Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc.
San Jose, California, United States
Aridis is a clinical stage biotech focusing on lung infections. Its portfolio includes anti-infective candidates and a human mAb platform. It has 2 mAbs in Phase 2a clinical t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 3:15 pm. Room Hearst.
Aridis Pharmaceuticals, Inc.
Track: A
City: San Jose
State: California
Country: United States
Ownership: PRIVATE
Aridis is a clinical stage biotech focusing on lung infections. Its portfolio includes anti-infective candidates and a human mAb platform. It has 2 mAbs in Phase 2a clinical testing in acute pneumonia and two anti-infective candidates at IND.

Visit: http://www.aridispharma.com
Connect with Aridis Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2015
Asceneuron SA
Asceneuron SA
Lausanne, Switzerland
Asceneuron is a preclinical biopharmaceutical company developing therapeutics for orphan tauopathies and improved symptomatic drugs for Alzheimer’s disease. The company expe...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Asceneuron SA

Asceneuron SA is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:45 am. Room Hearst.
Asceneuron SA
Track: A
City: Lausanne
Country: Switzerland
Ownership: PRIVATE
Asceneuron is a preclinical biopharmaceutical company developing therapeutics for orphan tauopathies and improved symptomatic drugs for Alzheimer’s disease. The company expects that its lead small molecule tau program will enter clinical development in early 2015.

Visit: http://www.asceneuron.com
Connect with Asceneuron SA on partnering360®

Biotech Showcase™ 2015
Asterias Biotherapeutics
Asterias Biotherapeutics
(NYSE:AST)
Menlo Park, California, United States
Asterias Biotherapeutics develops products based on its core technology platforms of pluripotent stem sells and allogeneic dendritic cell immunotherapies. It has two clinical ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Asterias Biotherapeutics

Asterias Biotherapeutics is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 10:00 am. Room Mission II.
Asterias Biotherapeutics
Track: C
City: Menlo Park
State: California
Country: United States
Ownership: PUBLIC
Ticker: AST
Stock exchange: NYSE
Asterias Biotherapeutics develops products based on its core technology platforms of pluripotent stem sells and allogeneic dendritic cell immunotherapies. It has two clinical stage programs, one AST-OPC1 for spinal cord injuries and one AST-VAC2 for lung cancer.

Visit: http://www.asteriasbiotherapeutics.com/
Connect with Asterias Biotherapeutics on partnering360®

Biotech Showcase™ 2015
Athersys, Inc.
Athersys, Inc.
(NASDAQ:ATHX)
Cleveland, Ohio, United States
Athersys is a clinical stage cell therapy company targeting neurological conditions, cardiovascular disease, inflammatory and immune disorders as well as other conditions. It...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Athersys, Inc.

Athersys, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:00 am. Room Mission II.
Athersys, Inc.
Track: C
City: Cleveland
State: Ohio
Country: United States
Ownership: PUBLIC
Ticker: ATHX
Stock exchange: NASDAQ
Athersys is a clinical stage cell therapy company targeting neurological conditions, cardiovascular disease, inflammatory and immune disorders as well as other conditions. It’s lead programs include a Phase 2 study in ischemic stroke and a Phase 2 study in acute myocardial infarction.

Visit: http://www.Athersys.com
Connect with Athersys, Inc. on partnering360®

Biotech Showcase™ 2015
Atossa Genetics, Inc.
Atossa Genetics, Inc.
(NASDAQ:ATOS)
Seattle, Washington, United States
Atossa Genetics is a commercial stage company targeting breast health through the development of laboratory services, medical devices and therapeutics.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Atossa Genetics, Inc.

Atossa Genetics, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 3:00 pm. Room Mission I.
Atossa Genetics, Inc.
Track: B
City: Seattle
State: Washington
Country: United States
Ownership: PUBLIC
Ticker: ATOS
Stock exchange: NASDAQ
Atossa Genetics is a commercial stage company targeting breast health through the development of laboratory services, medical devices and therapeutics.
Connect with Atossa Genetics, Inc. on partnering360®

Biotech Showcase™ 2015
Attana AB
Attana AB
Stockholm, Sweden
Attana AB is a commercial stage company that develops and markets biosensors to predict drug efficacy for pharmaceutical and diagnostic markets and for use by academic societi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Attana AB

Attana AB is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 2:30 pm. Room Hearst.
Attana AB
Track: A
City: Stockholm
Country: Sweden
Ownership: PRIVATE
Attana AB is a commercial stage company that develops and markets biosensors to predict drug efficacy for pharmaceutical and diagnostic markets and for use by academic societies.

Visit: http://www.attana.com
Connect with Attana AB on partnering360®

Biotech Showcase™ 2015
AuraSense Therapeutics
Skokie, United States
This early stage biopharmaceutical company is developing a new class of nucleic acid it calls ‘spherical nucleic acid’ (SNA). SNAs provide a 3D presentation of oligonucleo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AuraSense Therapeutics

AuraSense Therapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 8:45 am. Room Hearst.
Track: A
City: Skokie
Country: United States
Ownership: PRIVATE
This early stage biopharmaceutical company is developing a new class of nucleic acid it calls ‘spherical nucleic acid’ (SNA). SNAs provide a 3D presentation of oligonucleotides, which are able to enter cells and tissues without the use of transfection agents. It expects to file INDs in 2015.

Visit: http://www.aurasense.com
Connect with AuraSense Therapeutics on partnering360®

Biotech Showcase™ 2015
Avexxin AS
Avexxin AS
Trondheim, Norway
Avexxin is a clinical stage biopharmaceutical company developing and commercializing small molecule therapeutics for patients with chronic inflammatory conditions. It has a to...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Avexxin AS

Avexxin AS is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 3:00 pm. Room Hearst.
Avexxin AS
Track: A
City: Trondheim
Country: Norway
Ownership: PRIVATE
Avexxin is a clinical stage biopharmaceutical company developing and commercializing small molecule therapeutics for patients with chronic inflammatory conditions. It has a topical treatment for psoriasis in clinical development and pre-clinical assets for the treatment of rheumatoid arthritis.

Visit: http://www.avexxin.com
Connect with Avexxin AS on partnering360®

Biotech Showcase™ 2015
Aviara Pharmaceuticals
Aviara Pharmaceuticals
Houston, Texas, United States
Aviara develops small molecule pharmaceuticals to enhance the effectiveness of cell therapies and treat inflammatory diseases. Its lead clinical candidate is being developed f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Aviara Pharmaceuticals

Aviara Pharmaceuticals is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 8:00 am. Room Hearst.
Aviara Pharmaceuticals
Track: A
City: Houston
State: Texas
Country: United States
Ownership: PRIVATE
Aviara develops small molecule pharmaceuticals to enhance the effectiveness of cell therapies and treat inflammatory diseases. Its lead clinical candidate is being developed for the mobilization of hematopoietic stem sells to the peripheral blood for autologous transplant in patients with leukemia or lymphoma.

Visit: http://www.aviarapharma.com
Connect with Aviara Pharmaceuticals on partnering360®

Biotech Showcase™ 2015
Azevan Pharmaceuticals, Inc
Azevan Pharmaceuticals, Inc
Bethlehem, Pennsylvania, United States
Azevan’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurochormone involved in the pathophysiology of stress-related CNS disord...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Azevan Pharmaceuticals, Inc

Azevan Pharmaceuticals, Inc is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 9:15 am. Room Hearst.
Azevan Pharmaceuticals, Inc
Track: A
City: Bethlehem
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Azevan’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurochormone involved in the pathophysiology of stress-related CNS disorders, including neuropsychiatric symptoms in neurodegenerative disease, intermittent explosive disorder, PTSD, and major depression. Its most advanced compound is in Phase 2 trial for intermittent explosive disorder.

Visit: http://www.azevan.com
Connect with Azevan Pharmaceuticals, Inc on partnering360®

Biotech Showcase™ 2015
AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc.
New York, New York, United States
AzurRx BioPharma is a recently founded biotechnology company developing non-systemic, recombinant protein therapies for the treatment of gastroin¬testinal diseases and relate...


Share this:Email this pageShare this on LinkedInShare this on Twitter

AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 9:30 am. Room Mission I.
AzurRx BioPharma, Inc.
Track: B
City: New York
State: New York
Country: United States
AzurRx BioPharma is a recently founded biotechnology company developing non-systemic, recombinant protein therapies for the treatment of gastroin¬testinal diseases and related conditions. Our MS1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with ad¬ditional early-stage research being conducted for the prevention of hospital-acquired infections.

Visit: http://www.azurrx.com
Connect with AzurRx BioPharma, Inc. on partnering360®

Biotech Showcase™ 2015
BEAT BioTherapeutics
BEAT BioTherapeutics
Bellevue, Washington, United States
BEATBio is a preclinical stage company developing a gene therapy for the treatment of heart failure.


Share this:Email this pageShare this on LinkedInShare this on Twitter

BEAT BioTherapeutics

BEAT BioTherapeutics is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 9:15 am. Room Mission I.
BEAT BioTherapeutics
Track: B
City: Bellevue
State: Washington
Country: United States
Ownership: PRIVATE
Biotech Showcase™ 2015
Bell Biosystems, Inc.
Bell Biosystems, Inc.
Palo Alto, California, United States
Bell Biosystems is a pre-clinical synthetic biology company developing living biological tools that add complex function to cells. Its lead product is a living magnetic contra...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bell Biosystems, Inc.

Bell Biosystems, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 10:00 am. Room Mission I.
Bell Biosystems, Inc.
Track: B
City: Palo Alto
State: California
Country: United States
Ownership: PRIVATE
Bell Biosystems is a pre-clinical synthetic biology company developing living biological tools that add complex function to cells. Its lead product is a living magnetic contrast agent to address economic and technical roadblocks in the clinical practice of cell therapies.

Visit: http://www.bellbiosystems.com
Connect with Bell Biosystems, Inc. on partnering360®

Biotech Showcase™ 2015
Benitec Biopharma
Benitec Biopharma
(ASX:BLT)
Sydney, New South Wales, Australia
Benitc Biopharma develops treatments for chronic and life-threatening conditions based on its gene-silencing technology. Its clinical pipeline is focused on Hep C, Hep B, lung...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Benitec Biopharma

Benitec Biopharma is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 4:30 pm. Room Mission I.
Benitec Biopharma
Track: B
City: Sydney
State: New South Wales
Country: Australia
Ownership: PUBLIC
Ticker: BLT
Stock exchange: ASX
Benitc Biopharma develops treatments for chronic and life-threatening conditions based on its gene-silencing technology. Its clinical pipeline is focused on Hep C, Hep B, lung cancer and wet age-related macular degeneration. Its lead candidate targets Hep C and is in Phase1/2a

Visit: http://www.benitec.com
Connect with Benitec Biopharma on partnering360®

Biotech Showcase™ 2015
Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc.
(NASDAQ:BPTH)
Bellaire, Texas, United States
This is a clinical stage company developing therapeutic products using its liposomal delivery technology designed to systemically distribute nucleic acid drugs with a simple i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 3:30 pm. Room Powell.
Bio-Path Holdings, Inc.
Track: D
City: Bellaire
State: Texas
Country: United States
Ownership: PUBLIC
Ticker: BPTH
Stock exchange: NASDAQ
This is a clinical stage company developing therapeutic products using its liposomal delivery technology designed to systemically distribute nucleic acid drugs with a simple intravenous transfusion. Its lead candidate will start a Phase 2 study for blood cancers and is in preclinical studies for triple negative and inflammatory breast cancers.

Visit: http://www.biopathholdings.com
Connect with Bio-Path Holdings, Inc. on partnering360®

Biotech Showcase™ 2015
BioLineRx
BioLineRx
(NASDAQ:BLRX)
Jerusalem, Israel
BioLineRx is a clinical stage biopharmaceutical company that identifies, in-licenses and develops therapeutic candidates. It develops assets through pre-clinical or clinical s...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioLineRx

BioLineRx is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:30 am. Room Mission II.
BioLineRx
Track: C
City: Jerusalem
Country: Israel
Ownership: PUBLIC
Ticker: BLRX
Stock exchange: NASDAQ
BioLineRx is a clinical stage biopharmaceutical company that identifies, in-licenses and develops therapeutic candidates. It develops assets through pre-clinical or clinical stages and then partners with pharmaceutical companies for advanced clinical development or commercialization.

Visit: http://www.biolinerx.com
Connect with BioLineRx on partnering360®

Biotech Showcase™ 2015
Biological Dynamics, Inc.
Biological Dynamics, Inc.
San Diego, California, United States
Biological Dynamics is a clinical stage diagnostic company focused on cancer treatment response monitoring. It expects to receive a CE mark and 510k clearance in 2016.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biological Dynamics, Inc.

Biological Dynamics, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 8:45 am. Room Hearst.
Biological Dynamics, Inc.
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Biological Dynamics is a clinical stage diagnostic company focused on cancer treatment response monitoring. It expects to receive a CE mark and 510k clearance in 2016.

Visit: http://www.biologicaldynamics.com
Connect with Biological Dynamics, Inc. on partnering360®

Biotech Showcase™ 2015
BioMarker Strategies, LLC
BioMarker Strategies, LLC
Rockville, Maryland, United States
BioMarker Strategies is a privately-held tissue-based molecular diagnostics company that has developed the SnapPath® Cancer Diagnostics System. SnapPath uses fresh solid tum...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BioMarker Strategies, LLC

BioMarker Strategies, LLC is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:30 am. Room Mission I.
BioMarker Strategies, LLC
Track: B
City: Rockville
State: Maryland
Country: United States
Ownership: PRIVATE
BioMarker Strategies is a privately-held tissue-based molecular diagnostics company that has developed the SnapPath® Cancer Diagnostics System. SnapPath uses fresh solid tumor tissue samples to enable the automated and standardized generation of a new class of highly predictive biomarker tests to better inform the selection of which patients with solid tumor cancers are most likely to benefit from which targeted therapy or combination of therapies.

Visit: http://www.biomarkerstrategies.com
Connect with BioMarker Strategies, LLC on partnering360®

Biotech Showcase™ 2015
Bionomics
Bionomics
(ASX:BNO)
Thebarton, South Australia, Australia
Bionomics is creating new therapies for the treatment of cancer and diseases of the central nervous system such as anxiety, depression and Alzheimer’s based on four platform...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bionomics

Bionomics is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 9:00 am. Room Mission II.
Bionomics
Track: C
City: Thebarton
State: South Australia
Country: Australia
Ownership: PUBLIC
Ticker: BNO
Stock exchange: ASX
Bionomics is creating new therapies for the treatment of cancer and diseases of the central nervous system such as anxiety, depression and Alzheimer’s based on four platform technologies. Its lead candidate is a solid tumor targeting agent in Phase 2 trials.

Visit: http://www.bionomics.com.au
Connect with Bionomics on partnering360®

Biotech Showcase™ 2015
Bionure Inc
Bionure Inc
Menlo Park, California, United States
Bionure is a late-pre-clinical stage company developing SGK agonists for the treatment of orphan ophthalmologic diseases. Its lead candidate has been designated orphan for the...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Bionure Inc

Bionure Inc is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:45 am. Room Hearst.
Bionure Inc
Track: A
City: Menlo Park
State: California
Country: United States
Ownership: PRIVATE
Bionure is a late-pre-clinical stage company developing SGK agonists for the treatment of orphan ophthalmologic diseases. Its lead candidate has been designated orphan for the treatment of optic neuritis. And IND is expected in Q2 2015.

Visit: http://www.bionure.com
Connect with Bionure Inc on partnering360®

Biotech Showcase™ 2015
Biotecnol Ltd
Biotecnol Ltd
Welwyn Garden City, United Kingdom
Biotecnol is a pre-clinical stage company developing T and NK-cell activating, multi-targeting antibodies in the immune-oncology field.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biotecnol Ltd

Biotecnol Ltd is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 1:45 pm. Room Powell.
Biotecnol Ltd
Track: D
City: Welwyn Garden City
Country: United Kingdom
Ownership: PRIVATE
Biotecnol is a pre-clinical stage company developing T and NK-cell activating, multi-targeting antibodies in the immune-oncology field.

Visit: http://www.biotecnol.com
Connect with Biotecnol Ltd on partnering360®

Biotech Showcase™ 2015
Biotron Limited
Biotron Limited
(ASX:BIT)
Sydney, New South Wales, Australia
Biotron is a mid-stage drug development company targeting Hepatitis C and HIV. Its small molecule antiviral drug has shown good clinical efficacy against HCV. It has also has ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biotron Limited

Biotron Limited is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 9:00 am. Room Mission I.
Biotron Limited
Track: B
City: Sydney
State: New South Wales
Country: Australia
Ownership: PUBLIC
Ticker: BIT
Stock exchange: ASX
Biotron is a mid-stage drug development company targeting Hepatitis C and HIV. Its small molecule antiviral drug has shown good clinical efficacy against HCV. It has also has potential to attack HIV viral reservoirs which would contribute to the eradication of HIV.

Visit: http://www.biotron.com.au
Connect with Biotron Limited on partnering360®

Biotech Showcase™ 2015
Biovest International, Inc.
Biovest International, Inc.
Minneapolis, Minnesota, United States
Biovest International develops and manufactures personalized medicines. Its lead active immunotherapy has successfully completed phase 2 and Phase 3 clinical trials and is cur...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Biovest International, Inc.

Biovest International, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:45 am. Room Hearst.
Biovest International, Inc.
Track: A
City: Minneapolis
State: Minnesota
Country: United States
Ownership: PRIVATE
Biovest International develops and manufactures personalized medicines. Its lead active immunotherapy has successfully completed phase 2 and Phase 3 clinical trials and is currently undergoing regulatory review for marketing authorization in the EU.

Visit: http://www.biovest.com
Connect with Biovest International, Inc. on partnering360®

Biotech Showcase™ 2015
Blend Therapeutics
Blend Therapeutics
Watertown, Massachusetts, United States
Blend Therapeutics develops medicines that overcome the biological barriers that limit the effectiveness of cancer therapeutics. It is advancing a small molecule anticancer dr...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Blend Therapeutics

Blend Therapeutics is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 2:45 pm. Room Hearst.
Blend Therapeutics
Track: A
City: Watertown
State: Massachusetts
Country: United States
Ownership: PRIVATE
Blend Therapeutics develops medicines that overcome the biological barriers that limit the effectiveness of cancer therapeutics. It is advancing a small molecule anticancer drug candidate through pre-clinical development.

Visit: http://www.blendtx.com
Connect with Blend Therapeutics on partnering360®

Biotech Showcase™ 2015
BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics
(NASDAQ:BCLI)
Hackensack, New Jersey, United States
BrainStorm is a clinical stage company with a technology for cell-based delivery of neurotrophic factors. Its lead product is in a Phase 2 clinical trial at three US centers f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 4:30 pm. Room Mission II.
BrainStorm Cell Therapeutics
Track: C
City: Hackensack
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: BCLI
Stock exchange: NASDAQ
BrainStorm is a clinical stage company with a technology for cell-based delivery of neurotrophic factors. Its lead product is in a Phase 2 clinical trial at three US centers for ALS. It is also targeting Parkinson’s disease, MS and other CNS diseases.

Visit: http://www.brainstorm-cell.com
Connect with BrainStorm Cell Therapeutics on partnering360®

Biotech Showcase™ 2015
C4X Discovery
C4X Discovery
(AIM:C4XD.L)
Manchester, United Kingdom
C4X Discovery is a pre-clinical company with a platform for small molecule discovery that accurately measures the range and shapes a molecule can take in a solution. The platf...


Share this:Email this pageShare this on LinkedInShare this on Twitter

C4X Discovery

C4X Discovery is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 5:00 pm. Room Mission I.
C4X Discovery
Track: B
City: Manchester
Country: United Kingdom
Ownership: PUBLIC
Ticker: C4XD.L
Stock exchange: AIM
C4X Discovery is a pre-clinical company with a platform for small molecule discovery that accurately measures the range and shapes a molecule can take in a solution. The platform is indication independent, however the company is targeting addition, diabetes and COPD. It has collaborations with AZ, Takeda and Evotec.

Visit: http://www.c4xdiscovery.com
Connect with C4X Discovery on partnering360®

Biotech Showcase™ 2015
Canbex Therapeutics
Canbex Therapeutics
London, United Kingdom
Canbex Therapeutics has a Phase 2 ready compound that it hopes will be the first well-tolerated treatment for uncontrolled muscle movement in multiple sclerosis and other diso...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Canbex Therapeutics

Canbex Therapeutics is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 9:45 am. Room Hearst.
Canbex Therapeutics
Track: A
City: London
Country: United Kingdom
Ownership: PRIVATE
Canbex Therapeutics has a Phase 2 ready compound that it hopes will be the first well-tolerated treatment for uncontrolled muscle movement in multiple sclerosis and other disorders. The compound is an orally-active small molecule.

Visit: http://www.canbex.co.uk
Connect with Canbex Therapeutics on partnering360®

Biotech Showcase™ 2015
Capella Therapeutics
San Diego, California, United States
Capella Therapeutics has discovered and is developing compounds to selectively inhibit the growth of cancer cells that carry either primary or secondary T790M mutations. Its l...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Capella Therapeutics

Capella Therapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:15 am. Room Hearst.
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Capella Therapeutics has discovered and is developing compounds to selectively inhibit the growth of cancer cells that carry either primary or secondary T790M mutations. Its lead compound has been shown to be highly effective in treating non-small cell lung cancers that have demonstrated resistance toward Tarceva and Iressa.

Visit: http://www.capellatherapeutics.com
Connect with Capella Therapeutics on partnering360®

Biotech Showcase™ 2015
Capricor Therapeutics, Inc,
Capricor Therapeutics, Inc,
(OTCQB:CAPR)
Beverly Hills, California, United States
Capricor develops therapeutics for the treatment of cardiovascular disease. Its lead product is an allogeneic adult stem cell therapy for heart disease that is in Phase 2 in i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Capricor Therapeutics, Inc,

Capricor Therapeutics, Inc, is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 10:30 am. Room Mission II.
Capricor Therapeutics, Inc,
Track: C
City: Beverly Hills
State: California
Country: United States
Ownership: PUBLIC
Ticker: CAPR
Stock exchange: OTCQB
Capricor develops therapeutics for the treatment of cardiovascular disease. Its lead product is an allogeneic adult stem cell therapy for heart disease that is in Phase 2 in ischemic heart disease and Duchenne Muscular Dystrophy.

Visit: http://www.capricor.com
Connect with Capricor Therapeutics, Inc, on partnering360®

Biotech Showcase™ 2015
Capstone Therapeutics, Inc.
Capstone Therapeutics, Inc.
(OTCQB:CAPS)
Tempe, Arizona, United States
Capstone Therapeutics/LipimetiX Development is a clinical stage biotechnology company developing a new class of cardiovascular drug. Native Apolipoprotein E is recognized as a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Capstone Therapeutics, Inc.

Capstone Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 1:45 pm. Room Mission II.
Capstone Therapeutics, Inc.
Track: C
City: Tempe
State: Arizona
Country: United States
Ownership: PUBLIC
Ticker: CAPS
Stock exchange: OTCQB
Capstone Therapeutics/LipimetiX Development is a clinical stage biotechnology company developing a new class of cardiovascular drug. Native Apolipoprotein E is recognized as a fundamental regulator of cholesterol and lipid metabolism. The company's family of Apo E mimetic peptides target orphan, generic lipid disorders.

Visit: http://www.capstonethx.com/
Connect with Capstone Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2015
CEL-SCI Corporation
CEL-SCI Corporation
(NYSE-M:CVM)
Vienna, Virginia, United States
CEL-SCI is an advanced stage immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. It is currently conducting a ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CEL-SCI Corporation

CEL-SCI Corporation is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 11:30 am. Room Powell.
CEL-SCI Corporation
Track: D
City: Vienna
State: Virginia
Country: United States
Ownership: PUBLIC
Ticker: CVM
Stock exchange: NYSE-M
CEL-SCI is an advanced stage immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. It is currently conducting a Phase 3 trial for the treatment of head and neck cancer and a Phase 1 study with the US Navy in HIV/HPV co-infected patients.

Visit: http://www.cel-sci.com
Connect with CEL-SCI Corporation on partnering360®

Biotech Showcase™ 2015
Cell Source Ltd.
Cell Source Ltd.
(OTCQB:CLCS)
Tel Aviv, Israel
Cell Source is a pre-clinical stage immunotherapy and regenerative medicine company. Its technology relates to the regulation of immune tolerance to effectively treat ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cell Source Ltd.

Cell Source Ltd. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 4:00 pm. Room Mission II.
Cell Source Ltd.
Track: C
City: Tel Aviv
Country: Israel
Ownership: PUBLIC
Ticker: CLCS
Stock exchange: OTCQB
Cell Source is a pre-clinical stage immunotherapy and regenerative medicine company. Its technology relates to the regulation of immune tolerance to effectively treat blood cancers and nonmalignant congenital diseases.

Visit: http://www.cell-source.com
Connect with Cell Source Ltd. on partnering360®

Biotech Showcase™ 2015
Cell Therapy Limited
Cell Therapy Limited
Cardiff, United Kingdom
Cell Therapy is a clinical stage cell therapy company that has completed a Phase 2a trial demonstrating in situ myocardial regeneration with clinical and statistically signifi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cell Therapy Limited

Cell Therapy Limited is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:15 am. Room Mission I.
Cell Therapy Limited
Track: B
City: Cardiff
Country: United Kingdom
Ownership: PRIVATE
Cell Therapy is a clinical stage cell therapy company that has completed a Phase 2a trial demonstrating in situ myocardial regeneration with clinical and statistically significant improvement in LVEF, scar reduction and improved quality of life.

Visit: http://www.celltherapyltd.com
Connect with Cell Therapy Limited on partnering360®

Biotech Showcase™ 2015
Cellceutix
Cellceutix
(OTCBB:CTIX)
Beverly, Massachusetts, United States
Cellceutix is a therapeutic antibody company that recently completed a Phase 2 study. The company has compounds in clinical trials for cancers, psoriasis and oral mucositis. A...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cellceutix

Cellceutix is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 2:00 pm. Room Powell.
Cellceutix
Track: D
City: Beverly
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: CTIX
Stock exchange: OTCBB
Cellceutix is a therapeutic antibody company that recently completed a Phase 2 study. The company has compounds in clinical trials for cancers, psoriasis and oral mucositis. Additional trials are planned for diabetic foot infections, eye and ear infections, anti-fungal and gram-negative drug resistant bacteria.

Visit: http://www.cellceutix.com
Connect with Cellceutix on partnering360®

Biotech Showcase™ 2015
Cellectar Biosciences
Cellectar Biosciences
(NASDAQ:CLRB)
Madison, Wisconsin, United States
Cellectar Biosciences is a clinical stage oncology company that uses a technology that permits selective delivery of a variety of agents to cancer cells. Its lead candidate is...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cellectar Biosciences

Cellectar Biosciences is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 3:00 pm. Room Mission II.
Cellectar Biosciences
Track: C
City: Madison
State: Wisconsin
Country: United States
Ownership: PUBLIC
Ticker: CLRB
Stock exchange: NASDAQ
Cellectar Biosciences is a clinical stage oncology company that uses a technology that permits selective delivery of a variety of agents to cancer cells. Its lead candidate is a Phase 2 small molecule currently being evaluated in patients with glioblastoma.

Visit: http://www.cellectar.com
Connect with Cellectar Biosciences on partnering360®

Biotech Showcase™ 2015
Cellular Biomedicine Group Inc.
Cellular Biomedicine Group Inc.
(NASDAQ:CBMG)
Palo Alto, California, United States
Cellular Biomedicine is a clinical stage regenerative medicine and immune cell company with operations in China. It is aging diseases and cancer in the Chinese market and expe...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cellular Biomedicine Group Inc.

Cellular Biomedicine Group Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:30 am. Room Powell.
Cellular Biomedicine Group Inc.
Track: D
City: Palo Alto
State: California
Country: United States
Ownership: PUBLIC
Ticker: CBMG
Stock exchange: NASDAQ
Cellular Biomedicine is a clinical stage regenerative medicine and immune cell company with operations in China. It is aging diseases and cancer in the Chinese market and expects to have Phase 2a interim data on its lead product for knee osteoarthritis in Q1 2015.
Connect with Cellular Biomedicine Group Inc. on partnering360®

Biotech Showcase™ 2015
CereSpir, Incorporated
CereSpir, Incorporated
New York, New York, United States
CereSpir’s lead product has completed a Phase 2 study in people with mild cognitive impairment, and the company is currently finalizing the design of the Phase 3 clinical pr...


Share this:Email this pageShare this on LinkedInShare this on Twitter

CereSpir, Incorporated

CereSpir, Incorporated is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 9:30 am. Room Hearst.
CereSpir, Incorporated
Track: A
City: New York
State: New York
Country: United States
Ownership: PRIVATE
CereSpir’s lead product has completed a Phase 2 study in people with mild cognitive impairment, and the company is currently finalizing the design of the Phase 3 clinical protocol in consultation with KOLs and the FDA. It aims to initiate Phase 3 trials in 2015.

Visit: http://www.cerespir.com
Connect with CereSpir, Incorporated on partnering360®

Biotech Showcase™ 2015
Cesca Therapeuticss
Cesca Therapeuticss
(NASDAQ:KOOL)
Rancho Cordova, California, United States
Cesca Therapeutics is a clinical company focused cell-based therapeutics for use in regenerative medicine. Its lead therapeutic technology platform is in trials for the treame...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cesca Therapeuticss

Cesca Therapeuticss is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:00 am. Room Mission II.
Cesca Therapeuticss
Track: C
City: Rancho Cordova
State: California
Country: United States
Ownership: PUBLIC
Ticker: KOOL
Stock exchange: NASDAQ
Cesca Therapeutics is a clinical company focused cell-based therapeutics for use in regenerative medicine. Its lead therapeutic technology platform is in trials for the treament of acute myocardio infarction, critical limb ischemia and orthopedic injuries.

Visit: http://www.cescatherapeutics.com
Connect with Cesca Therapeuticss on partnering360®

Biotech Showcase™ 2015
CEVEC
CEVEC
Cologne, Germany
CEVEC is a clinical stage company developing CAP-based treatments for various indications including inherited angioedema, lung emphysema and inflammatory diseases.


Share this:Email this pageShare this on LinkedInShare this on Twitter

CEVEC

CEVEC is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 8:45 am. Room Mission I.
CEVEC
Track: B
City: Cologne
Country: Germany
Ownership: PRIVATE
CEVEC is a clinical stage company developing CAP-based treatments for various indications including inherited angioedema, lung emphysema and inflammatory diseases.

Visit: http://www.cevec.com
Connect with CEVEC on partnering360®

Biotech Showcase™ 2015
Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc.
(NASDAQ:CEMI)
Medford, New York, United States
Chembio is a commercial stage company that develops, manufactures, licenses and markets rapid diagnostic tests in the point-of-care testing market. It markets a branded test f...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 2:00 pm. Room Powell.
Chembio Diagnostics, Inc.
Track: D
City: Medford
State: New York
Country: United States
Ownership: PUBLIC
Ticker: CEMI
Stock exchange: NASDAQ
Chembio is a commercial stage company that develops, manufactures, licenses and markets rapid diagnostic tests in the point-of-care testing market. It markets a branded test for HIV and is developing diagnostic tests for Ebola, dengue fever and a specific cancer.

Visit: http://www.chembio.com
Connect with Chembio Diagnostics, Inc. on partnering360®

Biotech Showcase™ 2015
Chronos Therapeutics Ltd
Chronos Therapeutics Ltd
Oxford, United Kingdom
Chronos is a clinical stage company focused on disease of aging, neurodegeneration and osteoporosis. Its lead compound with target indications for osteoporosis and ALS is in P...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Chronos Therapeutics Ltd

Chronos Therapeutics Ltd is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:15 am. Room Mission I.
Chronos Therapeutics Ltd
Track: B
City: Oxford
Country: United Kingdom
Ownership: PRIVATE
Chronos is a clinical stage company focused on disease of aging, neurodegeneration and osteoporosis. Its lead compound with target indications for osteoporosis and ALS is in Phase 2 a/b clinical trials.

Visit: http://www.chronostherapeutics.com
Connect with Chronos Therapeutics Ltd on partnering360®

Biotech Showcase™ 2015
ContraFect Corporation
ContraFect Corporation
(NASDAQ:CFRX)
Yonkers, New York, United States
ContraFect is a preclinical biopharmaceutical company that discovers and develops therapeutic protein and antibody products for drug-resistant infectious diseases. It uses lys...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ContraFect Corporation

ContraFect Corporation is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:30 am. Room Powell.
ContraFect Corporation
Track: D
City: Yonkers
State: New York
Country: United States
Ownership: PUBLIC
Ticker: CFRX
Stock exchange: NASDAQ
ContraFect is a preclinical biopharmaceutical company that discovers and develops therapeutic protein and antibody products for drug-resistant infectious diseases. It uses lysine and antibody platforms to target conserved regions of either bacteria or viruses.

Visit: http://www.contrafect.com
Connect with ContraFect Corporation on partnering360®

Biotech Showcase™ 2015
Contravir Pharmaceuticals
Contravir Pharmaceuticals
(OTCBB:CTRV)
Edison, New Jersey, United States
ContraVir is a development stage biopharmaceutical company that discovers and develops targeted antiviral therapies. Its lead candidate is an orally available treatment for he...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Contravir Pharmaceuticals

Contravir Pharmaceuticals is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 3:30 pm. Room Mission II.
Contravir Pharmaceuticals
Track: C
City: Edison
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: CTRV
Stock exchange: OTCBB
ContraVir is a development stage biopharmaceutical company that discovers and develops targeted antiviral therapies. Its lead candidate is an orally available treatment for herpes zoster, or shingles, that is in Phsase 2b clinical trials.

Visit: http://www.contravir.com
Connect with Contravir Pharmaceuticals on partnering360®

Biotech Showcase™ 2015
Corbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc.
(OTCQB:CRBP)
Norwood, Massachusetts, United States
Corbus is a clinical stage biopharmaceutical company that develops therapies to treat inflammatory-fibrotic diseases with clear unmet needs. Its lead product candidate, an ora...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Corbus Pharmaceuticals, Inc.

Corbus Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 2:00 pm. Room Powell.
Corbus Pharmaceuticals, Inc.
Track: D
City: Norwood
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: CRBP
Stock exchange: OTCQB
Corbus is a clinical stage biopharmaceutical company that develops therapies to treat inflammatory-fibrotic diseases with clear unmet needs. Its lead product candidate, an oral anti-inflammatory drug, is scheduled to start Phase 2a trials for cystic fibrosis and systemic scleroderma in 2015.

Visit: http://www.corbuspharma.com
Connect with Corbus Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2015
Cornerstone Pharmaceuticals Inc.
New York, New York, United States
This clinical stage, oncology-focused pharmaceutical company has a platform that targets and disrupts energy metabolism in cancer cells. Its lead product is in clinical trials...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cornerstone Pharmaceuticals Inc.

Cornerstone Pharmaceuticals Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 9:45 am. Room Hearst.
Track: A
City: New York
State: New York
Country: United States
Ownership: PRIVATE
This clinical stage, oncology-focused pharmaceutical company has a platform that targets and disrupts energy metabolism in cancer cells. Its lead product is in clinical trials for solid tumors and hematologic malignancies.

Visit: http://www.cornerstonepharma.com/
Connect with Cornerstone Pharmaceuticals Inc. on partnering360®

Biotech Showcase™ 2015
Cortendo AB
Cortendo AB
(OTC:CRTOF)
Radnor, Pennsylvania, United States
Cortendo commercializes medicines for orphan endocrine disorders. Its lead product is currently being studied in a Phase 3 global trial for the treatment of Cushing’s syndro...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cortendo AB

Cortendo AB is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 3:30 pm. Room Powell.
Cortendo AB
Track: D
City: Radnor
State: Pennsylvania
Country: United States
Ownership: PUBLIC
Ticker: CRTOF
Stock exchange: OTC
Cortendo commercializes medicines for orphan endocrine disorders. Its lead product is currently being studied in a Phase 3 global trial for the treatment of Cushing’s syndrome.

Visit: http://www.cortendo.com/
Connect with Cortendo AB on partnering360®

Biotech Showcase™ 2015
Cortex Pharmaceuticals Inc.
Cortex Pharmaceuticals Inc.
(OTCBB:CORX)
Glen Rock, New Jersey, United States
Cortex is a biopharmaceutical company developing drug treatments for a variety of breathing disorders. Its lead programs, one for the treatment of obstructive sleep apnea and ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cortex Pharmaceuticals Inc.

Cortex Pharmaceuticals Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 4:30 pm. Room Mission I.
Cortex Pharmaceuticals Inc.
Track: B
City: Glen Rock
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: CORX
Stock exchange: OTCBB
Cortex is a biopharmaceutical company developing drug treatments for a variety of breathing disorders. Its lead programs, one for the treatment of obstructive sleep apnea and another for the treatment of drug-induced respiratory depression and central sleep apnea, have successfully completed Phase 2 clinical trials.

Visit: http://www.cortexpharm.com
Connect with Cortex Pharmaceuticals Inc. on partnering360®

Biotech Showcase™ 2015
Cortice Biosciences
Cortice Biosciences
New York, New York, United States
Cortice Biosciences is a clinical stage company developing treatments for large and rare oncologic and neurologic disease indications. Its lead programs address the treatment ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cortice Biosciences

Cortice Biosciences is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 9:15 am. Room Hearst.
Cortice Biosciences
Track: A
City: New York
State: New York
Country: United States
Ownership: PRIVATE
Cortice Biosciences is a clinical stage company developing treatments for large and rare oncologic and neurologic disease indications. Its lead programs address the treatment of brain cancers and neurodegenerative diseases and neurotransmitter pathway modulation for the treatment of cognitive impairment.

Visit: http://www.corticebiosciences.com
Connect with Cortice Biosciences on partnering360®

Biotech Showcase™ 2015
Crescendo Biologics Ltd
Crescendo Biologics Ltd
Cambridge, United Kingdom
Crescendo Biologics is a preclinical company that has developed an antibody fragment platform. It has recently completed a Series A financing that will allow it to develop a t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Crescendo Biologics Ltd

Crescendo Biologics Ltd is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 11:00 am. Room Hearst.
Crescendo Biologics Ltd
Track: A
City: Cambridge
Country: United Kingdom
Ownership: PRIVATE
Crescendo Biologics is a preclinical company that has developed an antibody fragment platform. It has recently completed a Series A financing that will allow it to develop a topical biologic for psoriasis and as well as discovery phase oncology products.

Visit: http://www.crescendobiologics.com
Connect with Crescendo Biologics Ltd on partnering360®

Biotech Showcase™ 2015
Cristal Therapeutics
Cristal Therapeutics
maastricht, Netherlands
Cristal Therapeutics is a preclinical stage company developing nanomedicines based on its polymeric technology. It expects to start clinical trials on its lead product designe...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cristal Therapeutics

Cristal Therapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:00 am. Room Hearst.
Cristal Therapeutics
Track: A
City: maastricht
Country: Netherlands
Cristal Therapeutics is a preclinical stage company developing nanomedicines based on its polymeric technology. It expects to start clinical trials on its lead product designed to treat various solid tumors in Q2 2015.

Visit: http://www.cristaltherapeutics.com
Connect with Cristal Therapeutics on partnering360®

Biotech Showcase™ 2015
Critical Outcome Technologies Inc.
Critical Outcome Technologies Inc.
(TSX-V:COT)
London, Ontario, Canada
Critical Outcomes Technologies is a preclinical drug development company using bioinformatics to increase the speed and efficiency of drug discovery and preclinical developmen...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Critical Outcome Technologies Inc.

Critical Outcome Technologies Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 4:00 pm. Room Powell.
Critical Outcome Technologies Inc.
Track: D
City: London
State: Ontario
Country: Canada
Ownership: PUBLIC
Ticker: COT
Stock exchange: TSX-V
Critical Outcomes Technologies is a preclinical drug development company using bioinformatics to increase the speed and efficiency of drug discovery and preclinical development. It is targeting diseases including cancers, MRSA, HIV and MS. Its lead product is being prepared for a Phase 1 study in early 2015.

Visit: http://www.criticaloutcome.com
Connect with Critical Outcome Technologies Inc. on partnering360®

Biotech Showcase™ 2015
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
(NASDAQ:CYCC)
Berkeley Heights, New Jersey, United States
Cyclacel’s lead drug candidate in a Phase 3 trial that is now over 90% enrolled and is being conducted under an SPA with the FDA as a front-line treatment for AML in the eld...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 3:30 pm. Room Powell.
Cyclacel Pharmaceuticals, Inc.
Track: D
City: Berkeley Heights
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: CYCC
Stock exchange: NASDAQ
Cyclacel’s lead drug candidate in a Phase 3 trial that is now over 90% enrolled and is being conducted under an SPA with the FDA as a front-line treatment for AML in the elderly. The drug is also being studied for MDS and solid tumors in combination with its CDK inhibitor.

Visit: http://www.cyclacel.com
Connect with Cyclacel Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2015
Cynapsus Therapeutics Inc
Cynapsus Therapeutics Inc
(OTCQB:CYNAF)
Toronto, Ontario, Canada
Cynapsus is a specialty pharmaceutical company developing a sublingual thin film strip for the acute rescue of ‘off’ motor symptoms of Parkinson’s disease. Its lead cand...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cynapsus Therapeutics Inc

Cynapsus Therapeutics Inc is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 11:00 am. Room Powell.
Cynapsus Therapeutics Inc
Track: D
City: Toronto
State: Ontario
Country: Canada
Ownership: PUBLIC
Ticker: CYNAF
Stock exchange: OTCQB
Cynapsus is a specialty pharmaceutical company developing a sublingual thin film strip for the acute rescue of ‘off’ motor symptoms of Parkinson’s disease. Its lead candidate is a reformulation of the only approved drug to rescue patients from ‘off’ episodes. It expects to submit an NDA in 2016.

Visit: http://www.cynapsus.ca
Connect with Cynapsus Therapeutics Inc on partnering360®

Biotech Showcase™ 2015
Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc.
(NASDAQ:CYTX)
San Diego, California, United States
Cytori is a clinical stage cell therapy company developing treatments for cardiovascular disease and soft tissue injuries and burns. It is targeting the treatment of chronic i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Cytori Therapeutics, Inc.

Cytori Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 3:30 pm. Room Mission II.
Cytori Therapeutics, Inc.
Track: C
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: CYTX
Stock exchange: NASDAQ
Cytori is a clinical stage cell therapy company developing treatments for cardiovascular disease and soft tissue injuries and burns. It is targeting the treatment of chronic ischemic heart failure through internal clinical development efforts and to develop a treatment for thermal burns combined with radiation injury under a contract from BARDA.

Visit: http://www.cytori.com
Connect with Cytori Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2015
DARA BioSciences, Inc.
DARA BioSciences, Inc.
(NASDAQ:DARA)
Raleigh, North Carolina, United States
DARA Biosciences is a commercialized oncology supportive care pharmaceutical company that offers a synergistic portfolio of medicines to help cancer patients adhere to their t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DARA BioSciences, Inc.

DARA BioSciences, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 3:00 pm. Room Mission I.
DARA BioSciences, Inc.
Track: B
City: Raleigh
State: North Carolina
Country: United States
Ownership: PUBLIC
Ticker: DARA
Stock exchange: NASDAQ
DARA Biosciences is a commercialized oncology supportive care pharmaceutical company that offers a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage the side effects of treatment.

Visit: http://www.darabio.com
Connect with DARA BioSciences, Inc. on partnering360®

Biotech Showcase™ 2015
DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc.
Vancouver, British Columbia, Canada
DelMar Pharmaceuticals develops and commercializes proven cancer therapies in new orphan drug indications. Its lead drug candidate is currently undergoing clinical trials in t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday , January 14 at 1:45 pm. Room Mission II .
DelMar Pharmaceuticals, Inc.
Track: C
City: Vancouver
State: British Columbia
Country: Canada
DelMar Pharmaceuticals develops and commercializes proven cancer therapies in new orphan drug indications. Its lead drug candidate is currently undergoing clinical trials in the US as a potential treatment for refractory gioblastoma multiforme.

Visit: http://www.delmarpharma.com/
Connect with DelMar Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2015
Dipexium Pharmaceuticals
Dipexium Pharmaceuticals
(NASDAQ:DPRX)
New York, New York, United States
Dipexium is conducting pivotal Phase 3 trials on its topical antibiotic cream targeting the treatment of mild infections of diabetic foot ulcers as well as other skin infectio...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Dipexium Pharmaceuticals

Dipexium Pharmaceuticals is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 4:30 pm. Room Powell.
Dipexium Pharmaceuticals
Track: D
City: New York
State: New York
Country: United States
Ownership: PUBLIC
Ticker: DPRX
Stock exchange: NASDAQ
Dipexium is conducting pivotal Phase 3 trials on its topical antibiotic cream targeting the treatment of mild infections of diabetic foot ulcers as well as other skin infections including those caused by resistant bacteria or ‘superbugs.’

Visit: http://www.dipexiumpharmaceuticals.com
Connect with Dipexium Pharmaceuticals on partnering360®

Biotech Showcase™ 2015
EIP PHARMA
EIP PHARMA
Cambridge, Massachusetts, United States
EIP Pharma is developing an investigational drug that specifically targets inflammation in the brain, which recent testing indicates is a critical driver of disease progressio...


Share this:Email this pageShare this on LinkedInShare this on Twitter

EIP PHARMA

EIP PHARMA is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 4:00 pm. Room Hearst.
EIP PHARMA
Track: A
City: Cambridge
State: Massachusetts
Country: United States
EIP Pharma is developing an investigational drug that specifically targets inflammation in the brain, which recent testing indicates is a critical driver of disease progression in Alzheimer's diesease. The company expects to initiate its first Phse 2 clinical trial in patients with Alzheimer's in early 2015.

Visit: http://www.eippharma.com
Connect with EIP PHARMA on partnering360®

Biotech Showcase™ 2015
Elastagen Pty Ltd
Elastagen Pty Ltd
Sydney, New South Wales, Australia
Elastagen is a clinical stage medical company that is using the human protein elastin to naturally rejuvenate, repair or regenerate damaged and aged tissues with applications ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Elastagen Pty Ltd

Elastagen Pty Ltd is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 8:30 am. Room Hearst.
Elastagen Pty Ltd
Track: A
City: Sydney
State: New South Wales
Country: Australia
Ownership: PRIVATE
Elastagen is a clinical stage medical company that is using the human protein elastin to naturally rejuvenate, repair or regenerate damaged and aged tissues with applications in aesthetics, scar remodelling, would repair and surgical adhesives.

Visit: http://www.elastagen.com
Connect with Elastagen Pty Ltd on partnering360®

Biotech Showcase™ 2015
Ellume
Ellume
East Brisbane, Queensland, Australia
Ellume is a consumer diagnostic company developing a non-invasive, ultra-sensitive home test for influenza. Validation trials are planned for 2015 and it expects to market the...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Ellume

Ellume is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:45 am. Room Mission I.
Ellume
Track: B
City: East Brisbane
State: Queensland
Country: Australia
Ownership: PRIVATE
Ellume is a consumer diagnostic company developing a non-invasive, ultra-sensitive home test for influenza. Validation trials are planned for 2015 and it expects to market the product in 2016 with a suggested retain price of between $20-$25 USD.

Visit: http://www.ellume.com.au
Connect with Ellume on partnering360®

Biotech Showcase™ 2015
Embera NeuroTherapeutics
Embera NeuroTherapeutics
Sudbury, Massachusetts, United States
Embera is developing a patented drug combination to address smoking cessation and cocaine dependence. The FDA has completed its review of the company’s IND submission and a ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Embera NeuroTherapeutics

Embera NeuroTherapeutics is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 10:00 am. Room Hearst.
Embera NeuroTherapeutics
Track: A
City: Sudbury
State: Massachusetts
Country: United States
Ownership: PRIVATE
Embera is developing a patented drug combination to address smoking cessation and cocaine dependence. The FDA has completed its review of the company’s IND submission and a Phase 1 study in otherwise health smokers is set to proceed.

Visit: http://www.emberaneuro.com
Connect with Embera NeuroTherapeutics on partnering360®

Biotech Showcase™ 2015
EnGeneIC Ltd
EnGeneIC Ltd
Lane Cove West, New South Wales, Australia
EnGeneIC Limited is a clinical stage biopharmaceutical company that aims to commercialize products for the targeted delivery of drugs and functional nucleic acids used...


Share this:Email this pageShare this on LinkedInShare this on Twitter

EnGeneIC Ltd

EnGeneIC Ltd is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 8:30 am. Room Hearst.
EnGeneIC Ltd
Track: A
City: Lane Cove West
State: New South Wales
Country: Australia
Ownership: PRIVATE
EnGeneIC Limited is a clinical stage biopharmaceutical company that aims to commercialize products for the targeted delivery of drugs and functional nucleic acids used in the treatment of cancer.

Visit: http://www.engeneic.com
Connect with EnGeneIC Ltd on partnering360®

Biotech Showcase™ 2015
Enumeral
Enumeral
(OTCQB:ENUM)
Cambridge, Massachusetts, United States
Enumeral is a preclinical stage company developing antibody immunotherapies for cancer, inflammatory and autoimmune diseases. Its platform enables the measurement of d...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Enumeral

Enumeral is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 2:30 pm. Room Mission I.
Enumeral
Track: B
City: Cambridge
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: ENUM
Stock exchange: OTCQB
Enumeral is a preclinical stage company developing antibody immunotherapies for cancer, inflammatory and autoimmune diseases. Its platform enables the measurement of drug effects in a patient-specific manner.

Visit: http://www.enumeral.com
Connect with Enumeral on partnering360®

Biotech Showcase™ 2015
Etubics Corporation
Etubics Corporation
Seattle, Washington, United States
Etubics is a clinical stage company with immunotherapy programs oncology and infectious diseases including Ebola, universal influenza and Lassa. Its platform technology has br...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Etubics Corporation

Etubics Corporation is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 9:45 am. Room Misson I.
Etubics Corporation
Track: B
City: Seattle
State: Washington
Country: United States
Ownership: PRIVATE
Etubics is a clinical stage company with immunotherapy programs oncology and infectious diseases including Ebola, universal influenza and Lassa. Its platform technology has broad applications to induce cell mediated and antibody responses and allows for rapid development vaccines.

Visit: http://www.etubics.com
Connect with Etubics Corporation on partnering360®

Biotech Showcase™ 2015
Fate Therapeutics, Inc.
Fate Therapeutics, Inc.
(NASDAQ:FATE)
San Diego, California, United States
Fate is a clinical stage biopharmaceutical company that discovers and develops pharmacologic modulators of adult stem cells to treat life-threatening diseases. It’s ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Fate Therapeutics, Inc.

Fate Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 11:30 am. Room Mission II.
Fate Therapeutics, Inc.
Track: C
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: FATE
Stock exchange: NASDAQ
Fate is a clinical stage biopharmaceutical company that discovers and develops pharmacologic modulators of adult stem cells to treat life-threatening diseases. It’s leading candidate in a Phase 2 clinical trials.
Connect with Fate Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2015
Fibrocell Science
Fibrocell Science
(NASDAQ:FCSC)
Exton, Pennsylvania, United States
Fibrocell is a clinical stage company that uses autologous fibroblasts to treat rare skin diseases. Its lead orphan candidate uses genetically-modified fibroblasts is ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Fibrocell Science

Fibrocell Science is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 11:00 am. Room Mission II.
Fibrocell Science
Track: C
City: Exton
State: Pennsylvania
Country: United States
Ownership: PUBLIC
Ticker: FCSC
Stock exchange: NASDAQ
Fibrocell is a clinical stage company that uses autologous fibroblasts to treat rare skin diseases. Its lead orphan candidate uses genetically-modified fibroblasts is in late stage preclinical development for recessive dystrophic epidermolysis bullosa. A Phase 2 for a second compound is in progress for vocal cord scarring.

Visit: http://www.fibrocellscience.com
Connect with Fibrocell Science on partnering360®

Biotech Showcase™ 2015
FLAG Therapeutics
FLAG Therapeutics
Raleigh, North Carolina, United States
FLAG is a preclinical company with 2 classes of small molecule oncology therapeutics. One has both broad antiangiogenic inhibition and anticancer effects and is being ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

FLAG Therapeutics

FLAG Therapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:00 am. Room Hearst.
FLAG Therapeutics
Track: A
City: Raleigh
State: North Carolina
Country: United States
Ownership: PRIVATE
FLAG is a preclinical company with 2 classes of small molecule oncology therapeutics. One has both broad antiangiogenic inhibition and anticancer effects and is being developed as a treatment of glioblastoma. The class is selective to the FR-Alpha receptor which is unique to certain ovarian, NSCLC, colon and kidney cancers.

Visit: http://www.FlagTherapeutics.com
Connect with FLAG Therapeutics on partnering360®

Biotech Showcase™ 2015
FluoroPharma Medical
FluoroPharma Medical
(OTC:FPMI)
Montclair, New Jersey, United States
FluoroPharma Medical is a clinical stage biopharmaceutical company that discovers, develops and commercializes molecular imaging pharmaceuticals with initial applications in t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

FluoroPharma Medical

FluoroPharma Medical is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 9:30 am. Room Mission II.
FluoroPharma Medical
Track: C
City: Montclair
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: FPMI
Stock exchange: OTC
FluoroPharma Medical is a clinical stage biopharmaceutical company that discovers, develops and commercializes molecular imaging pharmaceuticals with initial applications in the area of cardiology. Its two lead products are in Phase 2 trials.

Visit: http://www.fluoropharma.com
Connect with FluoroPharma Medical on partnering360®

Biotech Showcase™ 2015
Fusion Pharmaceuticals
Fusion Pharmaceuticals
Hamilton, Ontario, Canada
Fusion Pharmaceuticals is a clinical stage company developing precision radiopharmaceuticals for the diagnosis and treatment of human cancers that are currently untrea...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Fusion Pharmaceuticals

Fusion Pharmaceuticals is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 5:00 pm. Room Hearst.
Fusion Pharmaceuticals
Track: A
City: Hamilton
State: Ontario
Country: Canada
Ownership: PRIVATE
Fusion Pharmaceuticals is a clinical stage company developing precision radiopharmaceuticals for the diagnosis and treatment of human cancers that are currently untreatable. Its lead product combines an alpha radionuclide with the precise targeting of an antibody to cause selective cytotoxicity of tumor cells.

Visit: http://www.fusionpharma.com
Connect with Fusion Pharmaceuticals on partnering360®

Biotech Showcase™ 2015
Galmed Pharmaceuticals
Galmed Pharmaceuticals
(NASDAQ:GLMD)
Tel Aviv, Israel
Galmed is a clinical stage biopharmaceutical company developing and commercializing a once-daily, oral therapy for the treatment of liver disease. Its lead product is in Phase...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Galmed Pharmaceuticals

Galmed Pharmaceuticals is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:00 am. Room Powell.
Galmed Pharmaceuticals
Track: D
City: Tel Aviv
Country: Israel
Ownership: PUBLIC
Ticker: GLMD
Stock exchange: NASDAQ
Galmed is a clinical stage biopharmaceutical company developing and commercializing a once-daily, oral therapy for the treatment of liver disease. Its lead product is in Phase 2b clinical trials.

Visit: http://www.galmedpharma.com
Connect with Galmed Pharmaceuticals on partnering360®

Biotech Showcase™ 2015
Genomic Expression
Genomic Expression
New York, New York, United States
Genomic Expressions is a diagnostics company developing a pipeline of diagnostics for cancer that take advantage of next generation sequencing technology. It is launching its ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Genomic Expression

Genomic Expression is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 1:45 pm. Room Powell.
Genomic Expression
Track: D
City: New York
State: New York
Country: United States
Genomic Expressions is a diagnostics company developing a pipeline of diagnostics for cancer that take advantage of next generation sequencing technology. It is launching its first products in 2015.

Visit: http://www.genomicexpression.com/
Connect with Genomic Expression on partnering360®

Biotech Showcase™ 2015
GICARE PHARMA INC
GICARE PHARMA INC
Montreal-Ouest, Quebec, Canada
gIcare Pharma is a clinical stage company targeting gastroenterology and pain management. Its lead cadidate is a colonic analgesic drug to manage visceral pain during sedation...


Share this:Email this pageShare this on LinkedInShare this on Twitter

GICARE PHARMA INC

GICARE PHARMA INC is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 1:45 pm. Room Powell.
GICARE PHARMA INC
Track: D
City: Montreal-Ouest
State: Quebec
Country: Canada
Ownership: PRIVATE
gIcare Pharma is a clinical stage company targeting gastroenterology and pain management. Its lead cadidate is a colonic analgesic drug to manage visceral pain during sedation-free colonoscopy. It has completed Phase 2a.

Visit: http://www.gicarepharma.com
Connect with GICARE PHARMA INC on partnering360®

Biotech Showcase™ 2015
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc.
South San Francisco, California, United States
GBT is a preclinical stage biopharmaceutical company developing orally available small molecules for the treatment of severe chronic blood diseases. The company expects to ini...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:00 am. Room Hearst.
Global Blood Therapeutics, Inc.
Track: A
City: South San Francisco
State: California
Country: United States
Ownership: PRIVATE
GBT is a preclinical stage biopharmaceutical company developing orally available small molecules for the treatment of severe chronic blood diseases. The company expects to initiate clinical testing in January 2015.

Visit: http://www.globalbloodtx.com
Connect with Global Blood Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2015
GO Therapeutics
GO Therapeutics
Natick, Massachusetts, United States
GO Therapeutics uses technologies and platforms to harness the cancer glycoporteome to generate tumor-specific antibodies for immunotherapies. By making antibodies to hybrid a...


Share this:Email this pageShare this on LinkedInShare this on Twitter

GO Therapeutics

GO Therapeutics is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 3:00 pm. Room Hearst.
GO Therapeutics
Track: A
City: Natick
State: Massachusetts
Country: United States
Ownership: PRIVATE
GO Therapeutics uses technologies and platforms to harness the cancer glycoporteome to generate tumor-specific antibodies for immunotherapies. By making antibodies to hybrid antigens combining a tumor’s up-regulated protein express with that of a protein’s aberrant glycosylation pattern, it increases the tumor specificity of therapeutic antibodies.

Visit: http://www.gotherapeutics.com
Connect with GO Therapeutics on partnering360®

Biotech Showcase™ 2015
Gordian Biotechnologies, Inc.
Gordian Biotechnologies, Inc.
West Palm Beach, Florida, United States
Gordian Biotechnologies is a preclinical stage company addressing antibiotic resistance by developing a reversible beta-lactamase inhibitor. Its lead product attacks the resis...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Gordian Biotechnologies, Inc.

Gordian Biotechnologies, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:30 am. Room Hearst.
Gordian Biotechnologies, Inc.
Track: A
City: West Palm Beach
State: Florida
Country: United States
Ownership: PRIVATE
Gordian Biotechnologies is a preclinical stage company addressing antibiotic resistance by developing a reversible beta-lactamase inhibitor. Its lead product attacks the resistance mechanism of bacteria making them once again susceptible to existing antibiotics.

Visit: http://www.gordianbio.com
Connect with Gordian Biotechnologies, Inc. on partnering360®

Biotech Showcase™ 2015
Hansa Medical AB
Hansa Medical AB
(NASDAQ:HMED)
Lund, Sweden
Hansa Medical is a clinical stage biopharmaeutical company focused on immunomodulatory enzymes for the treatment of rare immunological conditions. Its lead candidate is curren...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Hansa Medical AB

Hansa Medical AB is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 1:45 pm. Room Mission II .
Hansa Medical AB
Track: C
City: Lund
Country: Sweden
Ownership: PUBLIC
Ticker: HMED
Stock exchange: NASDAQ
Hansa Medical is a clinical stage biopharmaeutical company focused on immunomodulatory enzymes for the treatment of rare immunological conditions. Its lead candidate is currently being evaulated in Phase 2 trials in HLA sensitized transplantation patients. In addiiton, treatment of several rare autoimmune conditions is being explored.

Visit: http://www.hansamedical.com
Connect with Hansa Medical AB on partnering360®

Biotech Showcase™ 2015
Harvard Apparatus Regenerative Technology (HART)
Holliston, Massachusetts, United States
This clinical-stage biotech company is making regenerated tracheas for transplant. Six compassionate care patients have been successfully treated. It has been granted orphan s...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Harvard Apparatus Regenerative Technology (HART)

Harvard Apparatus Regenerative Technology (HART) is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:00 am. Room Powell.
Track: D
City: Holliston
State: Massachusetts
Country: United States
This clinical-stage biotech company is making regenerated tracheas for transplant. Six compassionate care patients have been successfully treated. It has been granted orphan status in the US. The company is developing other esophageal products to treat esophageal cancer.

Visit: http://www.hartregen.com
Connect with Harvard Apparatus Regenerative Technology (HART) on partnering360®

Biotech Showcase™ 2015
Helomics Corporation
Pittsburgh, Pennsylvania, United States
Helomics is a commercialized personalized healthcare company in the oncology market. In additional to personalized medicine in cancer products, it offers laboratory services i...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Helomics Corporation

Helomics Corporation is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 1:45 pm. Room Mission I.
Track: B
City: Pittsburgh
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Helomics is a commercialized personalized healthcare company in the oncology market. In additional to personalized medicine in cancer products, it offers laboratory services including CRO, bioinformatics/databases and companion diagnostics.

Visit: http://www.helomics.com
Connect with Helomics Corporation on partnering360®

Biotech Showcase™ 2015
Hydra Biosciences
Hydra Biosciences
Cambridge, Massachusetts, United States
Hydra Biosciences is a clinical stage company that uses TRP ion channels to discover and develop medicines for people with serious diseases. Its most advanced product is being...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Hydra Biosciences

Hydra Biosciences is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 2:45 pm. Room Hearst.
Hydra Biosciences
Track: A
City: Cambridge
State: Massachusetts
Country: United States
Ownership: PRIVATE
Hydra Biosciences is a clinical stage company that uses TRP ion channels to discover and develop medicines for people with serious diseases. Its most advanced product is being studied for neuropathic pain and asthma, and it expects to begin human clinical trials in the first half of 2015.

Visit: http://www.hydrabio.com
Connect with Hydra Biosciences on partnering360®

Biotech Showcase™ 2015
iCeutica
iCeutica
King of Prussia, Pennsylvania, United States
This commercial stage company creates branded medicines in the areas of oncology, respiratory disease, musculoskeletal and connective tissue disorders. It has multiple approve...


Share this:Email this pageShare this on LinkedInShare this on Twitter

iCeutica

iCeutica is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 8:00 am. Room Hearst.
iCeutica
Track: A
City: King of Prussia
State: Pennsylvania
Country: United States
Ownership: PRIVATE
This commercial stage company creates branded medicines in the areas of oncology, respiratory disease, musculoskeletal and connective tissue disorders. It has multiple approved products and several products in various stages of clinical development.

Visit: http://www.iceutica.com
Connect with iCeutica on partnering360®

Biotech Showcase™ 2015
IGXBio
IGXBio
Lenexa, Kansas, United States
IGXBio is a clinical stage company targeting infectious diseases. The company has an approved IND with the FDA for a Phase 1/2 clinical trial in HIV infected patients.


Share this:Email this pageShare this on LinkedInShare this on Twitter

IGXBio

IGXBio is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:00 am. Room Hearst.
IGXBio
Track: A
City: Lenexa
State: Kansas
Country: United States
Ownership: PRIVATE
IGXBio is a clinical stage company targeting infectious diseases. The company has an approved IND with the FDA for a Phase 1/2 clinical trial in HIV infected patients.

Visit: http://igxbio.com/
Connect with IGXBio on partnering360®

Biotech Showcase™ 2015
Imanova Ltd
Imanova Ltd
London, United Kingdom
Imanova is a world-leading centre for imaging sciences and their high-value application to biomarker and early drug development.


Share this:Email this pageShare this on LinkedInShare this on Twitter

Imanova Ltd

Imanova Ltd is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 11:15 am. Room Hearst.
Imanova Ltd
Track: A
City: London
Country: United Kingdom
Ownership: PRIVATE
Imanova is a world-leading centre for imaging sciences and their high-value application to biomarker and early drug development.

Visit: http://www.imanova.co.uk
Connect with Imanova Ltd on partnering360®

Biotech Showcase™ 2015
Immunocore
Immunocore
Abingdon, United Kingdom
Immunocore is a clinical stage company with a platform of bi-specific proteins that has partnerships with Genentech, GSK, Medimmune and Lilly. Its lead product is in Phase 2a ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immunocore

Immunocore is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 3:15 pm. Room Hearst.
Immunocore
Track: A
City: Abingdon
Country: United Kingdom
Ownership: PRIVATE
Immunocore is a clinical stage company with a platform of bi-specific proteins that has partnerships with Genentech, GSK, Medimmune and Lilly. Its lead product is in Phase 2a trials in patients with metastatic melanoma.

Visit: http://www.immunocore.com
Connect with Immunocore on partnering360®

Biotech Showcase™ 2015
Immunome Inc.
Immunome Inc.
Fort Washington, Pennsylvania, United States
Immunome is a discovery stage company that is using an immunotherapy discovery engine to identify new cancer targets and therapies. The technology platform, co-invented by Rob...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immunome Inc.

Immunome Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 2:15 pm. Room Hearst.
Immunome Inc.
Track: A
City: Fort Washington
State: Pennsylvania
Country: United States
Ownership: PRIVATE
Immunome is a discovery stage company that is using an immunotherapy discovery engine to identify new cancer targets and therapies. The technology platform, co-invented by Robert Weinberg at MIT’s Whitehead Institute, has enabled the company to simultaneously discover multiple cancer antigens paired with native human antibodies that attack cancer cells.
Connect with Immunome Inc. on partnering360®

Biotech Showcase™ 2015
Immunomic Therapeutics
Immunomic Therapeutics
Rockville, Maryland, United States
ITI is commercializing a vaccine development platform through the development of product candidates in various stages of clinical testing. It is focused on the treatment on al...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immunomic Therapeutics

Immunomic Therapeutics is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 9:30 am. Room Hearst.
Immunomic Therapeutics
Track: A
City: Rockville
State: Maryland
Country: United States
Ownership: PRIVATE
ITI is commercializing a vaccine development platform through the development of product candidates in various stages of clinical testing. It is focused on the treatment on allergic diseases.

Visit: http://www.immunomix.com
Connect with Immunomic Therapeutics on partnering360®

Biotech Showcase™ 2015
Immunovaccine Inc.
Immunovaccine Inc.
(TSXV:IMV)
Halifax, Nova Scotia, Canada
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines. It has advanced two T cell activation therapies through Phase 1 human trials. It al...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Immunovaccine Inc.

Immunovaccine Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:30 am. Room Mission II.
Immunovaccine Inc.
Track: C
City: Halifax
State: Nova Scotia
Country: Canada
Ownership: PUBLIC
Ticker: IMV
Stock exchange: TSXV
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines. It has advanced two T cell activation therapies through Phase 1 human trials. It also has an infectious disease pipeline that includes a vaccine for respiratory syncytial virus and a collaboration with the NIH for vaccines for Ebola and anthrax.

Visit: http://www.imvaccine.com
Connect with Immunovaccine Inc. on partnering360®

Biotech Showcase™ 2015
Inovio Pharmaceuticals
Inovio Pharmaceuticals
(NASDAQ:INO)
Plymouth Meeting, Pennsylvania, United States
Inovio is a clinical stage company that is developing immunotherapies that activate immune responses to prevent and treat disease that show clinically significant efficacy wit...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Inovio Pharmaceuticals

Inovio Pharmaceuticals is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 10:30 am. Room Powell.
Inovio Pharmaceuticals
Track: D
City: Plymouth Meeting
State: Pennsylvania
Country: United States
Ownership: PUBLIC
Ticker: INO
Stock exchange: NASDAQ
Inovio is a clinical stage company that is developing immunotherapies that activate immune responses to prevent and treat disease that show clinically significant efficacy with a favorable safety profile.

Visit: http://www.inovio.com
Connect with Inovio Pharmaceuticals on partnering360®

Biotech Showcase™ 2015
Integene
Integene
Miami, Florida, United States
Integene is a preclinical company developing a platform for gene therapy to treat a broad range of vascular diseases including peripheral arterial disease, critical li...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Integene

Integene is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 2:00 pm. Room Hearst.
Integene
Track: A
City: Miami
State: Florida
Country: United States
Ownership: PRIVATE
Integene is a preclinical company developing a platform for gene therapy to treat a broad range of vascular diseases including peripheral arterial disease, critical limb ischemia and coronary artery disease. The company is initially focusing on critical limb ischemia that may qualify for orphan drug designation.

Visit: http://www.integene-int.com
Connect with Integene on partnering360®

Biotech Showcase™ 2015
Intellia
Cambridge, Massachusetts, United States
Intellia is a development stage biotech company developing CRISPR/Cas9 gene editing technology that permits the editing of any gene in any organism with simplicity and flexibi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Intellia

Intellia is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:15 am. Room Mission I.
Track: B
City: Cambridge
State: Massachusetts
Country: United States
Ownership: PRIVATE
Intellia is a development stage biotech company developing CRISPR/Cas9 gene editing technology that permits the editing of any gene in any organism with simplicity and flexibility. It has a broad IP portfolio covering the application of this technology for human therapeutic use.
Connect with Intellia on partnering360®

Biotech Showcase™ 2015
IntelliCyt Corporation
IntelliCyt Corporation
Albuquerque, New Mexico, United States
IntelliCyt is a commercial growth stage life sciences tools company that develops systems that help researchers gain a better understanding of cells and their role in disease....


Share this:Email this pageShare this on LinkedInShare this on Twitter

IntelliCyt Corporation

IntelliCyt Corporation is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 5:15 pm. Room Hearst.
IntelliCyt Corporation
Track: A
City: Albuquerque
State: New Mexico
Country: United States
IntelliCyt is a commercial growth stage life sciences tools company that develops systems that help researchers gain a better understanding of cells and their role in disease. Its instrumentation, software and reagent products are used by wide range of life sciences organizations.

Visit: http://www.intellicyt.com
Connect with IntelliCyt Corporation on partnering360®

Biotech Showcase™ 2015
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc.
Westport, Connecticut, United States
This specialty pharmaceutical company develops novel chemotherapeutic products that use advanced imaging, formulation science and immunology in what it calls in situ c...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 2:15 pm. Room Hearst.
Intensity Therapeutics, Inc.
Track: A
City: Westport
State: Connecticut
Country: United States
Ownership: PRIVATE
This specialty pharmaceutical company develops novel chemotherapeutic products that use advanced imaging, formulation science and immunology in what it calls in situ chemovaccination. It is a preclinical, development stage company that has had a Type B pre-NDA meeting with the FDA.

Visit: http://www.intensitytherapeutics.com
Connect with Intensity Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2015
International Stem Cell Corporation
International Stem Cell Corporation
(OTCQB:ISCO)
Carlsbad, California, United States
International Stem Cell is an early clinical stage regenerative medicine company developing novel stem cell based therapies and biomedical products. Its core technology can be...


Share this:Email this pageShare this on LinkedInShare this on Twitter

International Stem Cell Corporation

International Stem Cell Corporation is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 5:00 pm. Room Powell.
International Stem Cell Corporation
Track: D
City: Carlsbad
State: California
Country: United States
Ownership: PUBLIC
Ticker: ISCO
Stock exchange: OTCQB
International Stem Cell is an early clinical stage regenerative medicine company developing novel stem cell based therapies and biomedical products. Its core technology can be used to create clinical-grade cells and tissue for allogeneic therapy that are histocompatical with hundreds of millions of people.

Visit: http://www.internationalstemcell.com
Connect with International Stem Cell Corporation on partnering360®

Biotech Showcase™ 2015
Intezyne
Tampa, Florida, United States
Intezyne is a development stage oncology company. Its lead asset is a small molecule with a new mechanism of action targeting down-regulation of GRP78 a major cancer cell resi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Intezyne

Intezyne is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 3:15 pm. Room Hearst.
Track: A
City: Tampa
State: Florida
Country: United States
Ownership: PRIVATE
Intezyne is a development stage oncology company. Its lead asset is a small molecule with a new mechanism of action targeting down-regulation of GRP78 a major cancer cell resistance protein. GRP78 is preferentially expressed on the tumor cell surface, enabling specific tumor cell targeting and liming the impact on healthy cells.
Connect with Intezyne on partnering360®

Biotech Showcase™ 2015
Invion Limited
Invion Limited
(ASX:IVX)
Brisbane, Queensland, Australia
Invion is a clinical stage life sciences company developing treatments for inflammatory diseases including asthma, COPD, cystic fibrosis and lupus. It has three drug candidate...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Invion Limited

Invion Limited is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 4:30 pm. Room Mission I.
Invion Limited
Track: B
City: Brisbane
State: Queensland
Country: Australia
Ownership: PUBLIC
Ticker: IVX
Stock exchange: ASX
Invion is a clinical stage life sciences company developing treatments for inflammatory diseases including asthma, COPD, cystic fibrosis and lupus. It has three drug candidates in development including two in Phase 2 trials, one to treat inflammatory airway diseases and one for the treatment of autoimmune diseases.

Visit: http://www.inviongroup.com/
Connect with Invion Limited on partnering360®

Biotech Showcase™ 2015
Isarna Therapeutics
Isarna Therapeutics
Munich, Germany
Isarna develops TGF-ß inhibitors to fight cancer and treat ophthalmic and fibrotic diseases. It is advancing a pipeline of novel oligonucleotides and combination modalities t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Isarna Therapeutics

Isarna Therapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 1:45 pm. Room Hearst.
Isarna Therapeutics
Track: A
City: Munich
Country: Germany
Ownership: PRIVATE
Isarna develops TGF-ß inhibitors to fight cancer and treat ophthalmic and fibrotic diseases. It is advancing a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. Its most advanced lead compound will enter the clinic in 2015.

Visit: http://www.isarna-therapeutics.com
Connect with Isarna Therapeutics on partnering360®

Biotech Showcase™ 2015
JDP Therapeutics Inc
JDP Therapeutics Inc
LANSDALE, Pennsylvania, United States
JDP Therapeutics is a clinical Phase 3 stage specialty pharmaceutical company that develops small molecule therapeutics to treat acute allergic reactions, primarily in...


Share this:Email this pageShare this on LinkedInShare this on Twitter

JDP Therapeutics Inc

JDP Therapeutics Inc is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 4:30 pm. Room Hearst.
JDP Therapeutics Inc
Track: A
City: LANSDALE
State: Pennsylvania
Country: United States
Ownership: PRIVATE
JDP Therapeutics is a clinical Phase 3 stage specialty pharmaceutical company that develops small molecule therapeutics to treat acute allergic reactions, primarily in a hospital setting. Its lead product has completed its first Phase 3 clinical study.

Visit: http://www.jdptherapeutics.com/Pages/default.aspx
Connect with JDP Therapeutics Inc on partnering360®

Biotech Showcase™ 2015
Juventas Therapeutics
Juventas Therapeutics
Cleveland, Ohio, United States
Juventas develops biopharmaceuticals that activate the body’s natural regenerative repair processes. Its factor-based therapeutic approach provides an alternative to...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Juventas Therapeutics

Juventas Therapeutics is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 10:30 am. Room Mission I.
Juventas Therapeutics
Track: B
City: Cleveland
State: Ohio
Country: United States
Ownership: PRIVATE
Juventas develops biopharmaceuticals that activate the body’s natural regenerative repair processes. Its factor-based therapeutic approach provides an alternative to cellular therapy platforms. The company’s lead product is currently in Phase 2 clinical trials for heart failure and limb ischemia.

Visit: http://www.juventasinc.com
Connect with Juventas Therapeutics on partnering360®

Biotech Showcase™ 2015
Kalos Therapeutics, Inc.
Kalos Therapeutics, Inc.
San. Diego, California, United States
Kalos is a preclinical stage focused on hyperproliferative disorders targeting cancer and age related macular degeneration. It aims to translate the natural hemodynamic contro...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Kalos Therapeutics, Inc.

Kalos Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 9:00 am. Room Hearst.
Kalos Therapeutics, Inc.
Track: A
City: San. Diego
State: California
Country: United States
Ownership: PRIVATE
Kalos is a preclinical stage focused on hyperproliferative disorders targeting cancer and age related macular degeneration. It aims to translate the natural hemodynamic controls and antiproliferative activities of the ANO family of peptides into therapies.

Visit: http://www.kalostpx.com
Connect with Kalos Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2015
Karus Therapeutics
Karus Therapeutics
Oxfordshire, United Kingdom
Karus Therapeutics is a preclinical stage company developing medicines for the treatment of inflammatory disease and cancers. It has developed small molecule drugs from its is...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Karus Therapeutics

Karus Therapeutics is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:45 am. Room Mission I.
Karus Therapeutics
Track: B
City: Oxfordshire
Country: United Kingdom
Ownership: PRIVATE
Karus Therapeutics is a preclinical stage company developing medicines for the treatment of inflammatory disease and cancers. It has developed small molecule drugs from its isoform-selective P13K and HDAC6 inhibitor programs.

Visit: http://www.karustherapeutics.com
Connect with Karus Therapeutics on partnering360®

Biotech Showcase™ 2015
Kineta, Inc
Kineta, Inc
Seattle, Washington, United States
Kineta develops therapies through the end of Phase 1 and then licenses the drug to pharma on a global or regional basis. It is developing five drug programs with a focus on in...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Kineta, Inc

Kineta, Inc is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:00 am. Room Hearst.
Kineta, Inc
Track: A
City: Seattle
State: Washington
Country: United States
Ownership: PRIVATE
Kineta develops therapies through the end of Phase 1 and then licenses the drug to pharma on a global or regional basis. It is developing five drug programs with a focus on innate immunity and its role in autoimmune (Phase 1) and infectious disease (IND) and non-narcotic chronic pain (pre-IND).

Visit: http://www.kinetabio.com
Connect with Kineta, Inc on partnering360®

Biotech Showcase™ 2015
Kiromic
Lubbock, Texas, United States
Kiromic is a clinical-stage, immuno-oncology focused therapeutics and diagnostics company. Its development platform is built around a growing core of technologies: oral and in...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Kiromic

Kiromic is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:15 am. Room Hearst .
Track: A
City: Lubbock
State: Texas
Country: United States
Ownership: PRIVATE
Kiromic is a clinical-stage, immuno-oncology focused therapeutics and diagnostics company. Its development platform is built around a growing core of technologies: oral and injectible CTA-targeted immunotherapy, galectin inhibition, and gene therapy. Its most advanced product candidate, KiroVax, is a dendritic cell vaccine in Phase 1/2 for solid tumors.

Visit: http://www.kiromic.com
Connect with Kiromic on partnering360®

Biotech Showcase™ 2015
Kuros Biosurgery AG
Kuros Biosurgery AG
Switzerland, Zürich, Switzerland
Kuros Biosurgery is a clinical stage company developing a dural sealant product and orthobiologics products that are ready for Phase 3 and Phase 2 in trauma and spinal indicat...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Kuros Biosurgery AG

Kuros Biosurgery AG is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:00 am. Room Mission I.
Kuros Biosurgery AG
Track: B
City: Switzerland
State: Zürich
Country: Switzerland
Ownership: PRIVATE
Kuros Biosurgery is a clinical stage company developing a dural sealant product and orthobiologics products that are ready for Phase 3 and Phase 2 in trauma and spinal indications respectively.

Visit: http://www.kuros.ch
Connect with Kuros Biosurgery AG on partnering360®

Biotech Showcase™ 2015
Lion Biotechnologies
Lion Biotechnologies
(OTCBB:LBIO)
Woodland Hills, California, United States
This cancer immunotherapy company is developing an adoptive cell therapy with T lymphocytes derived from patients’ tumor or tumor-infiltrating lymphocytes. The company antic...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lion Biotechnologies

Lion Biotechnologies is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 3:00 pm. Room Powell.
Lion Biotechnologies
Track: D
City: Woodland Hills
State: California
Country: United States
Ownership: PUBLIC
Ticker: LBIO
Stock exchange: OTCBB
This cancer immunotherapy company is developing an adoptive cell therapy with T lymphocytes derived from patients’ tumor or tumor-infiltrating lymphocytes. The company anticipates initiating a Phase 2 clinical trial in 2015.

Visit: http://www.lbio.com
Connect with Lion Biotechnologies on partnering360®

Biotech Showcase™ 2015
Luoxis Diagnostics, Inc.
Luoxis Diagnostics, Inc.
Englewood, Colorado, United States
Luoxis is a diagnostic company developing a technology to measure redox potential – also called oxidation-reduction potential or ORP. Redox potential has been implicated in ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Luoxis Diagnostics, Inc.

Luoxis Diagnostics, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 4:00 pm. Room Hearst.
Luoxis Diagnostics, Inc.
Track: A
City: Englewood
State: Colorado
Country: United States
Ownership: PRIVATE
Luoxis is a diagnostic company developing a technology to measure redox potential – also called oxidation-reduction potential or ORP. Redox potential has been implicated in numerous critical injuries, illnesses and chronic conditions. Its product is approved for marketing in the EU and Canada.

Visit: http://www.luoxis.com
Connect with Luoxis Diagnostics, Inc. on partnering360®

Biotech Showcase™ 2015
Lysosomal Therapeutics
Lysosomal Therapeutics
Cambridge, Massachusetts, United States
Lysosomal Therapeutics is a discovery stage company that leverages lysosomal biology to develop small molecules for the treatment of neurodegenerative disease. It’s ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Lysosomal Therapeutics

Lysosomal Therapeutics is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 3:30 pm. Room Hearst.
Lysosomal Therapeutics
Track: A
City: Cambridge
State: Massachusetts
Country: United States
Ownership: PRIVATE
Lysosomal Therapeutics is a discovery stage company that leverages lysosomal biology to develop small molecules for the treatment of neurodegenerative disease. It’s lead program focuses on Gaucher’s and Parkinson’s disease and is in lead optimization.

Visit: http://www.lysosomaltx.com
Connect with Lysosomal Therapeutics on partnering360®

Biotech Showcase™ 2015
MabVax Therapeutics
MabVax Therapeutics
(OTCQB:MBVX)
San Diego, California, United States
MabVax is a clinical stage biotechnology company that is integrating human antibody discovery technology with multiple therapeutic cancer vaccines. It has two vaccines in late...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MabVax Therapeutics

MabVax Therapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:00 am. Room Powell.
MabVax Therapeutics
Track: D
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: MBVX
Stock exchange: OTCQB
MabVax is a clinical stage biotechnology company that is integrating human antibody discovery technology with multiple therapeutic cancer vaccines. It has two vaccines in late Phase 2 clinical trials for ovarian cancer and sarcoma. Its lead antibody should enter the clinic by mid-year for pancreatic cancer.

Visit: http://www.mabvax.com
Connect with MabVax Therapeutics on partnering360®

Biotech Showcase™ 2015
Mast Therapeutics, Inc.
Mast Therapeutics, Inc.
(NYSE-M:MSTX)
San Diego, California, United States
Mast Therapeutics is a clinical stage company focused on hematology. Its lead product, currently in a pivotal Phse 3 study, is the most clinically-advanced drug in development...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Mast Therapeutics, Inc.

Mast Therapeutics, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 2:30 pm. Room Mission I.
Mast Therapeutics, Inc.
Track: B
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: MSTX
Stock exchange: NYSE-M
Mast Therapeutics is a clinical stage company focused on hematology. Its lead product, currently in a pivotal Phse 3 study, is the most clinically-advanced drug in development for sickle cell patients. It also has drugs Phase 2 products for acute limb ischemia and acute decompensated heart failure.

Visit: http://www.masttherapeutics.com
Connect with Mast Therapeutics, Inc. on partnering360®

Biotech Showcase™ 2015
Matinas BioPharma
Matinas BioPharma
(OTCQB:MTNB)
Bedminster, New Jersey, United States
Matinas is a development stage biopharmaceutical company identifying and developing drugs to treat blood lipid abnormalities and cardiovascular and metabolic diseases. Its lea...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Matinas BioPharma

Matinas BioPharma is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 3:00 pm. Room Mission I.
Matinas BioPharma
Track: B
City: Bedminster
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: MTNB
Stock exchange: OTCQB
Matinas is a development stage biopharmaceutical company identifying and developing drugs to treat blood lipid abnormalities and cardiovascular and metabolic diseases. Its lead product is designed and formulated for applications in dyslipidemia and the company expects to initiate Phase 3 registration in 2015.

Visit: http://www.matinasbiopharma.com
Connect with Matinas BioPharma on partnering360®

Biotech Showcase™ 2015
MaxCyte, Inc.
MaxCyte, Inc.
Gaithersburg, Maryland, United States
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Using a scalable el...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MaxCyte, Inc.

MaxCyte, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 10:15 am. Room Mission I.
MaxCyte, Inc.
Track: B
City: Gaithersburg
State: Maryland
Country: United States
Ownership: PRIVATE
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Using a scalable electroporation process, MaxCyte’s proprietary cell transfection platform is used by pharmaceutical and biotechnology companies around the world to engineer cells for a wide range of applications.

Visit: http://www.maxcyte.com
Connect with MaxCyte, Inc. on partnering360®

Biotech Showcase™ 2015
Medgenics
Medgenics
(NYSE:MDGN)
Wayne, Pennsylvania, United States
Medgenics is a clinical stage company developing an ex vivo gene therapy platform for the treatment of rare and orphan diseases including renal anemia, beta thalassemi...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Medgenics

Medgenics is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 5:00 pm. Room Mission II.
Medgenics
Track: C
City: Wayne
State: Pennsylvania
Country: United States
Ownership: PUBLIC
Ticker: MDGN
Stock exchange: NYSE
Medgenics is a clinical stage company developing an ex vivo gene therapy platform for the treatment of rare and orphan diseases including renal anemia, beta thalassemia, MDS and short bowel syndrome. Its lead product is in Phase 2 clinical trials.

Visit: http://www.medgenics.com/index.php
Connect with Medgenics on partnering360®

Biotech Showcase™ 2015
Medicenna Therapeutics, Inc
Medicenna Therapeutics, Inc
Vancouver, British Columbia, Canada
Medicenna is a clinical stage oncology company with a lead product entering Phase 2b trails for recurrent glioblastoma following compelling efficacy over existing standard of ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Medicenna Therapeutics, Inc

Medicenna Therapeutics, Inc is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:00 am. Room Mission I.
Medicenna Therapeutics, Inc
Track: B
City: Vancouver
State: British Columbia
Country: Canada
Ownership: PRIVATE
Medicenna is a clinical stage oncology company with a lead product entering Phase 2b trails for recurrent glioblastoma following compelling efficacy over existing standard of care.

Visit: http://www.medicenna.com
Connect with Medicenna Therapeutics, Inc on partnering360®

Biotech Showcase™ 2015
Medigene AG
Medigene AG
(ETR:MDG1)
Planegg/Martinsried, Germany
Medigene is a commercial stage biotechnology company focused on the development of personalized T cell immunotherapies, particularly those related to haematological malignanci...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Medigene AG

Medigene AG is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:00 am. Room Powell.
Medigene AG
Track: D
City: Planegg/Martinsried
Country: Germany
Ownership: PUBLIC
Ticker: MDG1
Stock exchange: ETR
Medigene is a commercial stage biotechnology company focused on the development of personalized T cell immunotherapies, particularly those related to haematological malignancies. It is has one approved drug on the market, Veregen, and several programs in development for the treatment of various cancers.

Visit: http://www.medigene.com
Connect with Medigene AG on partnering360®

Biotech Showcase™ 2015
MedVax Technologies, Inc.
MedVax Technologies, Inc.
Miami Beach, Florida, United States
MedVax is a clinical stage biopharmaceutical company developing cancer vaccines. Its two lead products are focused on antigen presenting cells of the immune system. One has co...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MedVax Technologies, Inc.

MedVax Technologies, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 2:00 pm. Room Hearst.
MedVax Technologies, Inc.
Track: A
City: Miami Beach
State: Florida
Country: United States
Ownership: PRIVATE
MedVax is a clinical stage biopharmaceutical company developing cancer vaccines. Its two lead products are focused on antigen presenting cells of the immune system. One has completed Phase 2a clinical trials in small cell lung cancer and the other is completing a second Phase 1 study in solid tumors.

Visit: http://www.medvax.net
Connect with MedVax Technologies, Inc. on partnering360®

Biotech Showcase™ 2015
Metastat
Metastat
(OTCQB:MTST)
Boston , Massachusetts , United States
MetaStat is developing and commercializing epigenetic-based diagnostic tests for early, reliable prediction of systemic metastasis in breast, prostate, lung and colorectal can...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Metastat

Metastat is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 10:30 am. Room Mission II.
Metastat
Track: C
City: Boston
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: MTST
Stock exchange: OTCQB
MetaStat is developing and commercializing epigenetic-based diagnostic tests for early, reliable prediction of systemic metastasis in breast, prostate, lung and colorectal cancers. Its platform is built on identifying and understanding the tumor microenvironment and role of the Mena protein, a pathway for the development of systemic metastasis in solid tumors.

Visit: http://www.metastat.com
Connect with Metastat on partnering360®

Biotech Showcase™ 2015
Microbial Robotics
Microbial Robotics
Cincinnati, Ohio, United States
Microbial Robotics develops synthetic biology products. It generates revenues through early exits of synthetic biology-based BactoBots (bacteria) and ViruBots (viruses) non-op...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Microbial Robotics

Microbial Robotics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 5:00 pm. Room Hearst.
Microbial Robotics
Track: A
City: Cincinnati
State: Ohio
Country: United States
Ownership: PRIVATE
Microbial Robotics develops synthetic biology products. It generates revenues through early exits of synthetic biology-based BactoBots (bacteria) and ViruBots (viruses) non-operating subsidiaries. Company is cash flow positive with the next exit of one of its subsidiaries in 2015 with underway acquisition discussions.

Visit: http://www.MicrobialRobotics.com
Connect with Microbial Robotics on partnering360®

Biotech Showcase™ 2015
Midatech
Midatech
(AIM:MTPH)
Abingdon, United Kingdom
Midatech is an acquisitive clinical stage specialty pharma company focused on endocrinology, diabetes, neurology and ophthalmology. Its lead product is in Phase 2 clin...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Midatech

Midatech is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 3:00 pm. Room Powell.
Midatech
Track: D
City: Abingdon
Country: United Kingdom
Ownership: PUBLIC
Ticker: MTPH
Stock exchange: AIM
Midatech is an acquisitive clinical stage specialty pharma company focused on endocrinology, diabetes, neurology and ophthalmology. Its lead product is in Phase 2 clinical trials.
Connect with Midatech on partnering360®

Biotech Showcase™ 2015
Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc.
Montreal, Quebec, Canada
Milestone Pharmaceuticals is a clinical stage company that develops small molecule therapeutics for transient cardiovascular conditions. Its lead product is a treatmen...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:30 am. Room Mission I.
Milestone Pharmaceuticals Inc.
Track: B
City: Montreal
State: Quebec
Country: Canada
Ownership: PRIVATE
Milestone Pharmaceuticals is a clinical stage company that develops small molecule therapeutics for transient cardiovascular conditions. Its lead product is a treatment of paroxysmal supraventricular tachycardia that all allow patients to self-administer at the onset of symptoms. It will begin Phase 2 studies in 2015.

Visit: http://www.milestonepharma.com
Connect with Milestone Pharmaceuticals Inc. on partnering360®

Biotech Showcase™ 2015
MiNA Therapeutics
MiNA Therapeutics
London, United Kingdom
MiNA Therapeutics is a preclinical stage oncology company working on a class of medicines that selectively up-regulate proteins inside patient cells. Its RNA activatio...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MiNA Therapeutics

MiNA Therapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 8:15 am. Room Hearst.
MiNA Therapeutics
Track: A
City: London
Country: United Kingdom
Ownership: PRIVATE
MiNA Therapeutics is a preclinical stage oncology company working on a class of medicines that selectively up-regulate proteins inside patient cells. Its RNA activation platform enables up-regulation of beneficial proteins by selective and long lasting transcriptional activation of a target gene.

Visit: http://www.minatx.com
Connect with MiNA Therapeutics on partnering360®

Biotech Showcase™ 2015
MTG Biotherapeutics
San Diego, California, United States
MTG Biotherapeutics is seeking investment partners for the development and commercialization of MTG-201, a first-in-class anti-cancer viral protein delivery therapy that treat...


Share this:Email this pageShare this on LinkedInShare this on Twitter

MTG Biotherapeutics

MTG Biotherapeutics is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 8:00 am. Room Mission I.
Track: B
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
MTG Biotherapeutics is seeking investment partners for the development and commercialization of MTG-201, a first-in-class anti-cancer viral protein delivery therapy that treats cancer by a dual mechanism. MTG-201 represents the first clinical approach to treating cancer based on REIC deficiency with significant IP to 2035.

Visit: http://www.mtg-bio.com
Connect with MTG Biotherapeutics on partnering360®

Biotech Showcase™ 2015
Multimeric Biotherapeutics, Inc.
Multimeric Biotherapeutics, Inc.
La Jolla, California, United States
This early clinical stage immune-oncology company is using a ligand based technology platform to develop immune-oncology products and vaccines. Its lead products targe...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:15 am. Room Mission I.
Multimeric Biotherapeutics, Inc.
Track: B
City: La Jolla
State: California
Country: United States
Ownership: PRIVATE
This early clinical stage immune-oncology company is using a ligand based technology platform to develop immune-oncology products and vaccines. Its lead products target ovarian and prostate cancers.

Visit: http://www.multimericbio.com
Connect with Multimeric Biotherapeutics, Inc. on partnering360®

Biotech Showcase™ 2015
Nano3D Biosciences, Inc.
Nano3D Biosciences, Inc.
Houston, Texas, United States
Nano3D Biosciences is a commercial stage company that markets kits and services using magnetic 3D bioprinting to develop assays predictive of human drug response. Its technolo...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Nano3D Biosciences, Inc.

Nano3D Biosciences, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 10:15 am. Room Hearst.
Nano3D Biosciences, Inc.
Track: A
City: Houston
State: Texas
Country: United States
Ownership: PRIVATE
Nano3D Biosciences is a commercial stage company that markets kits and services using magnetic 3D bioprinting to develop assays predictive of human drug response. Its technology has applications in life sciences R&D, toxicology testing and personalized medicine. Its short-term goal is to market its system to address pre-term labor management.

Visit: http://www.n3dbio.com
Connect with Nano3D Biosciences, Inc. on partnering360®

Biotech Showcase™ 2015
NanoViricides, Inc
NanoViricides, Inc
(NYSE:NNVC)
Santa Monica, California, United States
NanoViricides is a preclinical nanobiotech company with a platform technology to rapidly create new targeting anti-virals. Human trials are planned in 2015 for Ebola and Fluci...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NanoViricides, Inc

NanoViricides, Inc is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:30 am. Room Powell.
NanoViricides, Inc
Track: D
City: Santa Monica
State: California
Country: United States
Ownership: PUBLIC
Ticker: NNVC
Stock exchange: NYSE
NanoViricides is a preclinical nanobiotech company with a platform technology to rapidly create new targeting anti-virals. Human trials are planned in 2015 for Ebola and Flucide (complicated influenza in hospitalized patients).

Visit: http://www.nanoviricides.com
Connect with NanoViricides, Inc on partnering360®

Biotech Showcase™ 2015
Navidea Biopharmaceuticals
Navidea Biopharmaceuticals
(NYSE:NAVB)
Dublin, Ohio, United States
Navidea is a commercial stage company that develops diagnostic and therapeutic radiopharmaceuticals. Its first product has US and European approval and is used to dete...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 2:30 pm. Room Mission I.
Navidea Biopharmaceuticals
Track: B
City: Dublin
State: Ohio
Country: United States
Ownership: PUBLIC
Ticker: NAVB
Stock exchange: NYSE
Navidea is a commercial stage company that develops diagnostic and therapeutic radiopharmaceuticals. Its first product has US and European approval and is used to determine the spread of cancer. The company also plans to apply its core molecule to therapeutics for arthritis, cancer and infectious diseases.

Visit: http://www.navidea.com
Connect with Navidea Biopharmaceuticals on partnering360®

Biotech Showcase™ 2015
NetBio
NetBio
Waltham, Massachusetts, United States
NetBio is commercializing products and services in the field of Rapid DNA Analysis. RDNA is performed in the field – at police stations, embassies, borders and ports – by ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NetBio

NetBio is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:00 am. Room Mission I.
NetBio
Track: B
City: Waltham
State: Massachusetts
Country: United States
Ownership: PRIVATE
NetBio is commercializing products and services in the field of Rapid DNA Analysis. RDNA is performed in the field – at police stations, embassies, borders and ports – by non-technical users when timely DNA information is needed. It has raised over $100M in non-dilutive funding to date.

Visit: http://www.netbio.com
Connect with NetBio on partnering360®

Biotech Showcase™ 2015
Neuralstem
Neuralstem
(NYSE-M:CUR)
Germantown, Maryland, United States
Neuralstem is a clinical stage company with a cell therapy/small molecule platform that is uses to develop CNS therapies using regionally specific human neural stem cells. It ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Neuralstem

Neuralstem is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 9:00 am. Room Powell.
Neuralstem
Track: D
City: Germantown
State: Maryland
Country: United States
Ownership: PUBLIC
Ticker: CUR
Stock exchange: NYSE-M
Neuralstem is a clinical stage company with a cell therapy/small molecule platform that is uses to develop CNS therapies using regionally specific human neural stem cells. It has two ongoing cell therapy clinical trials for ALS and chronic spinal cord injury.

Visit: http://www.neuralstem.com
Connect with Neuralstem on partnering360®

Biotech Showcase™ 2015
NeuroMetrix, Inc.
NeuroMetrix, Inc.
(NASDAQ:NURO)
Waltham, Massachusetts, United States
NeuroMetrix develops wearable medical technology and point-of-care tests to help patients and physicians better manage chronic pain, nerve diseases and sleep disorders. It has...


Share this:Email this pageShare this on LinkedInShare this on Twitter

NeuroMetrix, Inc.

NeuroMetrix, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 2:00 pm. Room Mission I.
NeuroMetrix, Inc.
Track: B
City: Waltham
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: NURO
Stock exchange: NASDAQ
NeuroMetrix develops wearable medical technology and point-of-care tests to help patients and physicians better manage chronic pain, nerve diseases and sleep disorders. It has FDA cleared prescription and OTC products and focuses on diabetic neuropathies.

Visit: http://www.neurometrix.com
Connect with NeuroMetrix, Inc. on partnering360®

Biotech Showcase™ 2015
Neurotrope, Inc.
Neurotrope, Inc.
(OTCQB:NTRP)
Newark, New Jersey, United States
Neurotrope is developing therapeutics for neurodegenerative diseases such as Alzheimer’s disease and orphan drug indications including Niemann Pick Type C and Fragile X Synd...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Neurotrope, Inc.

Neurotrope, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:30 am. Room Mission II.
Neurotrope, Inc.
Track: C
City: Newark
State: New Jersey
Country: United States
Ownership: PUBLIC
Ticker: NTRP
Stock exchange: OTCQB
Neurotrope is developing therapeutics for neurodegenerative diseases such as Alzheimer’s disease and orphan drug indications including Niemann Pick Type C and Fragile X Syndrome. The company’s lead compound is currently initiating a Phase 2a clinical trial for the treatment of AD. It is also developing a simple AD diagnostic test.

Visit: http://www.neurotropebioscience.com
Connect with Neurotrope, Inc. on partnering360®

Biotech Showcase™ 2015
Nexstim
Nexstim
helsinki, Finland
Nextim is a medical technology company aimed at improving rehabilitation for stroke patients with noninvasive neurostimulation. It has a marketed diagnostic, an FDA-cleared an...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Nexstim

Nexstim is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:00 am. Room Mission I.
Nexstim
Track: B
City: helsinki
Country: Finland
Ownership: PRIVATE
Nextim is a medical technology company aimed at improving rehabilitation for stroke patients with noninvasive neurostimulation. It has a marketed diagnostic, an FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation device. It also has a therapeutic in Phase 3.

Visit: http://www.nexstim.com
Connect with Nexstim on partnering360®

Biotech Showcase™ 2015
Nordic Nanovector SA
Nordic Nanovector SA
Oslo, Norway
This clinical stage company develops radioimmunotherapeutics for the treatment of severe cancers. Its lead product candidate is currently undergoing a Phase 1/2 clinical trial...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Nordic Nanovector SA

Nordic Nanovector SA is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:30 am. Room Mission I.
Nordic Nanovector SA
Track: B
City: Oslo
Country: Norway
Ownership: PRIVATE
This clinical stage company develops radioimmunotherapeutics for the treatment of severe cancers. Its lead product candidate is currently undergoing a Phase 1/2 clinical trial for the treatment of patients with non-Hodgkin Lymphoma.

Visit: http://www.nordicnanovector.com
Connect with Nordic Nanovector SA on partnering360®

Biotech Showcase™ 2015
Northwest Biotherapeutics
Northwest Biotherapeutics
(NASDAQ:NWBO)
Bethesda, Maryland, United States
Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, without the side effec...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Northwest Biotherapeutics

Northwest Biotherapeutics is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 5:00 pm. Room Mission II.
Northwest Biotherapeutics
Track: C
City: Bethesda
State: Maryland
Country: United States
Ownership: PUBLIC
Ticker: NWBO
Stock exchange: NASDAQ
Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, without the side effects of chemotherapy drugs. The Company has a broad platform technology for DCVax dendritic cell-based vaccines.

Visit: http://www.nwbio.com
Connect with Northwest Biotherapeutics on partnering360®

Biotech Showcase™ 2015
Nuvo Research Inc.
Nuvo Research Inc.
(TSX:NRI)
Mississauga, Ontario, Canada
Nuvo Research is a specialty pharmaceutical company with a diverse portfolio of products and technologies. It operates two business units, one devoted to topical products and ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Nuvo Research Inc.

Nuvo Research Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 4:00 pm. Room Mission II.
Nuvo Research Inc.
Track: C
City: Mississauga
State: Ontario
Country: Canada
Ownership: PUBLIC
Ticker: NRI
Stock exchange: TSX
Nuvo Research is a specialty pharmaceutical company with a diverse portfolio of products and technologies. It operates two business units, one devoted to topical products and technologies and another devoted to immunology. It has four FDA approved products and its lead product for allergic rhinitis is in Phase 2.

Visit: http://www.nuvoresearch.com
Connect with Nuvo Research Inc. on partnering360®

Biotech Showcase™ 2015
Omni Bio Pharmaceutical, Inc.
Omni Bio Pharmaceutical, Inc.
(OTCBB:OMBP)
Fort Collins, Colorado, United States
Omni Bio is an emerging biotech company aiming to revolutionize the way immune-medicated inflammatory diseases are treated. Its target indications include Type 1 diabe...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Omni Bio Pharmaceutical, Inc.

Omni Bio Pharmaceutical, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 3:30 pm. Room Mission I.
Omni Bio Pharmaceutical, Inc.
Track: B
City: Fort Collins
State: Colorado
Country: United States
Ownership: PUBLIC
Ticker: OMBP
Stock exchange: OTCBB
Omni Bio is an emerging biotech company aiming to revolutionize the way immune-medicated inflammatory diseases are treated. Its target indications include Type 1 diabetes, graft vs host disease, chronic gout as well as other inflammatory conditions.

Visit: http://www.omnibiopharma.com
Connect with Omni Bio Pharmaceutical, Inc. on partnering360®

Biotech Showcase™ 2015
OncoSec Medical Inc.
OncoSec Medical Inc.
(OTCQB:ONCS)
San Diego, California, United States
OncoSec Medical is a clinical stage company developing cancer immunotherapies. Its core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

OncoSec Medical Inc.

OncoSec Medical Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 9:00 am. Room Mission II.
OncoSec Medical Inc.
Track: C
City: San Diego
State: California
Country: United States
Ownership: PUBLIC
Ticker: ONCS
Stock exchange: OTCQB
OncoSec Medical is a clinical stage company developing cancer immunotherapies. Its core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeted agents. Its lead product is in Phase 2b clinical trials.

Visit: http://www.oncosec.com
Connect with OncoSec Medical Inc. on partnering360®

Biotech Showcase™ 2015
OncoTab, Inc.
OncoTab, Inc.
Charlotte, North Carolina, United States
OncoTab is a preclinical stage company developing products that span the lifecycle of cancer. Its platform had demonstrated diagnostic and therapeutic potential. It is...


Share this:Email this pageShare this on LinkedInShare this on Twitter

OncoTab, Inc.

OncoTab, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 9:00 am. Room Mission I.
OncoTab, Inc.
Track: B
City: Charlotte
State: North Carolina
Country: United States
Ownership: PRIVATE
OncoTab is a preclinical stage company developing products that span the lifecycle of cancer. Its platform had demonstrated diagnostic and therapeutic potential. It is currently conducting prospective clinical studies to detect breast cancer following suspicious mammograms.
Connect with OncoTab, Inc. on partnering360®

Biotech Showcase™ 2015
ONXEO S.A.
ONXEO S.A.
Paris, France
ONXEO is a commercial stage biotech focused on orphan oncology diseases. It has three products in advanced clinical development with potential applications for liver cancer, o...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ONXEO S.A.

ONXEO S.A. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 3:30 pm. Room Hearst.
ONXEO S.A.
Track: A
City: Paris
Country: France
Ownership: PRIVATE
ONXEO is a commercial stage biotech focused on orphan oncology diseases. It has three products in advanced clinical development with potential applications for liver cancer, oral mucostis and PTCL. It already has three products approved in either Europe or the US.

Visit: http://www.onxeo.com
Connect with ONXEO S.A. on partnering360®

Biotech Showcase™ 2015
ORIG3N
ORIG3N
Boston, Massachusetts, United States
ORIG3N is a preclinical stage biotech company that is developing treatments for rare genetically inherited disease based on cellular reprogramming technology. It curre...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ORIG3N

ORIG3N is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 5:00 pm. Room Hearst.
ORIG3N
Track: A
City: Boston
State: Massachusetts
Country: United States
Ownership: PRIVATE
ORIG3N is a preclinical stage biotech company that is developing treatments for rare genetically inherited disease based on cellular reprogramming technology. It current markets a direct to consumer bio-repository.

Visit: http://www.orig3n.com
Connect with ORIG3N on partnering360®

Biotech Showcase™ 2015
ORYX Translational Medicine
ORYX Translational Medicine
Baldham, Germany
ORYX develops promising cancer projects from research institutions and development through preclinical and clinical phases until proof of concept/efficacy. It oversees...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ORYX Translational Medicine

ORYX Translational Medicine is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 2:45 pm. Room Hearst.
ORYX Translational Medicine
Track: A
City: Baldham
Country: Germany
Ownership: PRIVATE
ORYX develops promising cancer projects from research institutions and development through preclinical and clinical phases until proof of concept/efficacy. It oversees a product portfolio of three projects currently in Phase 1/2a clinical trials.

Visit: http://www.oryx-medicine.com
Connect with ORYX Translational Medicine on partnering360®

Biotech Showcase™ 2015
ORYZON GENOMICS, S.A.
ORYZON GENOMICS, S.A.
Cornellà de Llobregat (Barcelona), Spain



Share this:Email this pageShare this on LinkedInShare this on Twitter

ORYZON GENOMICS, S.A.

ORYZON GENOMICS, S.A. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:45 am. Room Hearst.
ORYZON GENOMICS, S.A.
Track: A
City: Cornellà de Llobregat (Barcelona)
Country: Spain
Ownership: PRIVATE
Biotech Showcase™ 2015
Oxford BioMedica
Oxford BioMedica
(LSE:OXB)
Oxford, United Kingdom
Oxford BioMedica is a clinical stage gene and cell therapy company targeting markets in ophthalmology, CNS and oncology. It has contracts with Novartis covering licens...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Oxford BioMedica

Oxford BioMedica is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 4:00 pm. Room Mission II.
Oxford BioMedica
Track: C
City: Oxford
Country: United Kingdom
Ownership: PUBLIC
Ticker: OXB
Stock exchange: LSE
Oxford BioMedica is a clinical stage gene and cell therapy company targeting markets in ophthalmology, CNS and oncology. It has contracts with Novartis covering license to its IP and vector manufacture of its lead product.
Connect with Oxford BioMedica on partnering360®

Biotech Showcase™ 2015
Parnell
Parnell
(NASDAQ:PARN)
Overland Park, Kansas, United States
Parnell is a commercial stage animal pharmaceutical company with operations in drug development, manufacturing and commercialization. It has marketed products for catt...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Parnell

Parnell is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 9:30 am. Room Powell.
Parnell
Track: D
City: Overland Park
State: Kansas
Country: United States
Ownership: PUBLIC
Ticker: PARN
Stock exchange: NASDAQ
Parnell is a commercial stage animal pharmaceutical company with operations in drug development, manufacturing and commercialization. It has marketed products for cattle fertility and osteoarthritis in dogs and horses. It is developing new products for companion animals in osteoarthritis, dermatology, orthopedics, anesthetics and metabolic diseases.

Visit: http://www.parnell.com
Connect with Parnell on partnering360®

Biotech Showcase™ 2015
Pathoquest
Pathoquest
Paris, France
PathoQuest is a spin-out of the Institut Pasteur that is developing molecular diagnostics in the area of infectious disease that combine Whole Genome NGS and Cloud com...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Pathoquest

Pathoquest is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 1:45 pm. Room Hearst.
Pathoquest
Track: A
City: Paris
Country: France
Ownership: PRIVATE
PathoQuest is a spin-out of the Institut Pasteur that is developing molecular diagnostics in the area of infectious disease that combine Whole Genome NGS and Cloud computing-based software as a service. It is completing a clinical study and plans a clinical trial in the US in early 2015.

Visit: http://www.pathoquest.com
Connect with Pathoquest on partnering360®

Biotech Showcase™ 2015
PCI Biotech AS
PCI Biotech AS
(OSE Axess:PCIB)
Lysaker, Norway
PCI Biotech is a clinical stage company developing anti-cancer products and a CTL-inducer for therapeutic vaccination using its endosomal escape technology platform. The compa...


Share this:Email this pageShare this on LinkedInShare this on Twitter

PCI Biotech AS

PCI Biotech AS is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 2:30 pm. Room Mission II.
PCI Biotech AS
Track: C
City: Lysaker
Country: Norway
Ownership: PUBLIC
Ticker: PCIB
Stock exchange: OSE Axess
PCI Biotech is a clinical stage company developing anti-cancer products and a CTL-inducer for therapeutic vaccination using its endosomal escape technology platform. The company target head and neck and bile duct cancers by triggering endosomal escape of established anticancer agents.
Connect with PCI Biotech AS on partnering360®

Biotech Showcase™ 2015
Pediatric Bioscience, Inc.
Pediatric Bioscience, Inc.
San Diego, California, United States
This diagnostic company has developed a novel blood biomarker test for the largest known subtype of autism. The test will allow for earlier diagnosis and treatment of this spe...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Pediatric Bioscience, Inc.

Pediatric Bioscience, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 2:15 pm. Room Hearst.
Pediatric Bioscience, Inc.
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
This diagnostic company has developed a novel blood biomarker test for the largest known subtype of autism. The test will allow for earlier diagnosis and treatment of this specific form of autism. The company will make the test available in the Fall of 2015 through its CLIA laboratory service model.

Visit: http://www.pedbio.com
Connect with Pediatric Bioscience, Inc. on partnering360®

Biotech Showcase™ 2015
Phylogica Ltd
Phylogica Ltd
(ASX:PYC)
Subiaco. Perth, Western Australia, Australia
Phylogica is a discovery stage company that owns a therapeutic class of peptides. It has entered into five discovery collaborations with large pharmaceutical companies. It has...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Phylogica Ltd

Phylogica Ltd is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 4:30 pm. Room Powell.
Phylogica Ltd
Track: D
City: Subiaco. Perth
State: Western Australia
Country: Australia
Ownership: PUBLIC
Ticker: PYC
Stock exchange: ASX
Phylogica is a discovery stage company that owns a therapeutic class of peptides. It has entered into five discovery collaborations with large pharmaceutical companies. It has also recently launched a program to develop drugs against breast cancer.

Visit: http://www.phylogica.com
Connect with Phylogica Ltd on partnering360®

Biotech Showcase™ 2015
PixarBio Corporation
PixarBio Corporation
Medford, Massachusetts, United States
PixarBio, co-founded by Dr. Robert S. Langer of MIT and CEO Frank Reynolds, is a preclinical company that is researching and developing biomaterials to be used in combination ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

PixarBio Corporation

PixarBio Corporation is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 10:30 am. Room Mission I.
PixarBio Corporation
Track: B
City: Medford
State: Massachusetts
Country: United States
Ownership: PRIVATE
PixarBio, co-founded by Dr. Robert S. Langer of MIT and CEO Frank Reynolds, is a preclinical company that is researching and developing biomaterials to be used in combination with therapeutic agents to treat acute and chronic pain, spinal cord injury, epilepsy and Parkinson’s disease.

Visit: http://www.pixarbio.com
Connect with PixarBio Corporation on partnering360®

Biotech Showcase™ 2015
PlasmaTech Biopharmaceuticals, Inc.
PlasmaTech Biopharmaceuticals, Inc.
(NASDAQ:PTBI)
New York, New York, United States
PlasmaTech Biopharmaceuticals, Inc. is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting tw...


Share this:Email this pageShare this on LinkedInShare this on Twitter

PlasmaTech Biopharmaceuticals, Inc.

PlasmaTech Biopharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:30 am. Room Powell.
PlasmaTech Biopharmaceuticals, Inc.
Track: D
City: New York
State: New York
Country: United States
Ownership: PUBLIC
Ticker: PTBI
Stock exchange: NASDAQ
PlasmaTech Biopharmaceuticals, Inc. is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two distinct proprietary platforms, PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products.

Visit: http://www.plasmatechbio.com
Connect with PlasmaTech Biopharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2015
Polynoma
Polynoma
San Diego, California, United States
Polynoma is a clinical stage immuno-oncology company currently developing a therapeutic vaccine for the treatment of melamoma. It has commences a Phase 3 clinical trial for it...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Polynoma

Polynoma is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 4:00 pm. Room Hearst.
Polynoma
Track: A
City: San Diego
State: California
Country: United States
Ownership: PRIVATE
Polynoma is a clinical stage immuno-oncology company currently developing a therapeutic vaccine for the treatment of melamoma. It has commences a Phase 3 clinical trial for its polyvalent antigen vaccine that contains multiple antigens that are shed from human melanoma cell lines.

Visit: http://www.polynoma.com
Connect with Polynoma on partnering360®

Biotech Showcase™ 2015
Pre Diagnostics AS
Pre Diagnostics AS
Oslo, Norway
This preclinical company is developing a blood-based test for Alzheimer’s disease and pre-dementia. Amyloid plaque formations in AD can be monitored in blood macrophages whe...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Pre Diagnostics AS

Pre Diagnostics AS is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 3:45 pm. Room Hearst.
Pre Diagnostics AS
Track: A
City: Oslo
Country: Norway
Ownership: PRIVATE
This preclinical company is developing a blood-based test for Alzheimer’s disease and pre-dementia. Amyloid plaque formations in AD can be monitored in blood macrophages where impeded betaAmyloid-degradation signals disease onset. A new assay was successfully applied identifying pre-dementia clinical samples.

Visit: http://www.pre-diagnostics.com
Connect with Pre Diagnostics AS on partnering360®

Biotech Showcase™ 2015
Prevacus, Inc.
Prevacus, Inc.
Tallahassee, Florida, United States
Prevacus is a preclinical stage drug development company with a lead candidate that is a neurosteroid designed for nasal delivery following acute concussion for up to 14 days....


Share this:Email this pageShare this on LinkedInShare this on Twitter

Prevacus, Inc.

Prevacus, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:30 am. Room Hearst.
Prevacus, Inc.
Track: A
City: Tallahassee
State: Florida
Country: United States
Ownership: PRIVATE
Prevacus is a preclinical stage drug development company with a lead candidate that is a neurosteroid designed for nasal delivery following acute concussion for up to 14 days. It is currently completing IND enabling studies.

Visit: http://www.prevacus.com
Connect with Prevacus, Inc. on partnering360®

Biotech Showcase™ 2015
Prokarium Ltd
Prokarium Ltd
Keele, United Kingdom
Prokarium is a clinical stage vaccine company with a dual diarrhea and typhoid vaccine in Phase I clinical development and clostridium difficile and chlamydia vaccines in pre-...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Prokarium Ltd

Prokarium Ltd is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 4:15 pm. Room Hearst.
Prokarium Ltd
Track: A
City: Keele
Country: United Kingdom
Ownership: PRIVATE
Prokarium is a clinical stage vaccine company with a dual diarrhea and typhoid vaccine in Phase I clinical development and clostridium difficile and chlamydia vaccines in pre-clinical development. Its oral delivery platform can deliver any protein vaccine orally reducing cost and increasing stability.

Visit: http://www.prokarium.com
Connect with Prokarium Ltd on partnering360®

Biotech Showcase™ 2015
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc.
Milwaukee, Wisconsin, United States
Promentis is a discovery stage pharmaceutical company that is developing molecules for a variety of central nervous system disorders including schizophrenia, Parkinson...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Promentis Pharmaceuticals, Inc.

Promentis Pharmaceuticals, Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 4:45 pm. Room Hearst.
Promentis Pharmaceuticals, Inc.
Track: A
City: Milwaukee
State: Wisconsin
Country: United States
Ownership: PRIVATE
Promentis is a discovery stage pharmaceutical company that is developing molecules for a variety of central nervous system disorders including schizophrenia, Parkinson’s disease and pediatric disorders including autism.

Visit: http://www.promentispharma.com
Connect with Promentis Pharmaceuticals, Inc. on partnering360®

Biotech Showcase™ 2015
ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc.
(TSX:PLI)
Laval, Quebec, Canada
This clinical stage company specializes in bioseparations, plasma-derived therapeutics and small molecule development. It provides technologies for large-scale purification of...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 2:00 pm. Room Mission I.
ProMetic Life Sciences Inc.
Track: B
City: Laval
State: Quebec
Country: Canada
Ownership: PUBLIC
Ticker: PLI
Stock exchange: TSX
This clinical stage company specializes in bioseparations, plasma-derived therapeutics and small molecule development. It provides technologies for large-scale purification of biologics, drug development and the elimination of pathogens. It also uses its platform for internal discovery projects.

Visit: http://www.prometic.com
Connect with ProMetic Life Sciences Inc. on partnering360®

Biotech Showcase™ 2015
Protagen
Protagen
Dortmund, Germany
Protagen is a commercial stage diagnostic company that uses a personalized medicine approach to enable differential diagnosis and patient stratification for RA, systemic lupus...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Protagen

Protagen is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 10:30 am. Room Hearst.
Protagen
Track: A
City: Dortmund
Country: Germany
Ownership: PRIVATE
Protagen is a commercial stage diagnostic company that uses a personalized medicine approach to enable differential diagnosis and patient stratification for RA, systemic lupus erythematosus, MS and other diseases.

Visit: http://www.protagen.com
Connect with Protagen on partnering360®

Biotech Showcase™ 2015
Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc.
Milpitas, California, United States
Protagonist is a preclinical stage company discovering and developing orally stable peptides based on NCEs against validated inflammatory targets and GI diseases. It identifie...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc. is scheduled to present at Biotech Showcase™ 2015
Tuesday , January 13 at 2:30 pm. Room Hearst.
Protagonist Therapeutics Inc.
Track: A
City: Milpitas
State: California
Country: United States
Ownership: PRIVATE
Protagonist is a preclinical stage company discovering and developing orally stable peptides based on NCEs against validated inflammatory targets and GI diseases. It identified its first development candidate in 2014.

Visit: http://www.protagonist-inc.com
Connect with Protagonist Therapeutics Inc. on partnering360®

Biotech Showcase™ 2015
Protea Biosciences
Protea Biosciences
(OTCBB:PRGB)
Morgantown, West Virginia, United States
Protea Biosciences is a molecular information company providing solutions to the biopharmaceutical and life science industries. "Molecular information" refers to the generatio...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Protea Biosciences

Protea Biosciences is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 8:00 am. Room Hearst.
Protea Biosciences
Track: A
City: Morgantown
State: West Virginia
Country: United States
Ownership: PUBLIC
Ticker: PRGB
Stock exchange: OTCBB
Protea Biosciences is a molecular information company providing solutions to the biopharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the company's technology to identify and characterize the proteins, metabolites, lipids and other biomolecules.

Visit: http://www.proteabio.com
Connect with Protea Biosciences on partnering360®

Biotech Showcase™ 2015
ProteoTech Inc
ProteoTech Inc
Kirkland, Washington, United States
ProteoTech develops small molecule drugs for rare orphan amyloid diseases and disorders involvding misfolded proteins. Its lead product candidate is entering a Phase 1/2 clini...


Share this:Email this pageShare this on LinkedInShare this on Twitter

ProteoTech Inc

ProteoTech Inc is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:30 am. Room Mission I.
ProteoTech Inc
Track: B
City: Kirkland
State: Washington
Country: United States
Ownership: PRIVATE
ProteoTech develops small molecule drugs for rare orphan amyloid diseases and disorders involvding misfolded proteins. Its lead product candidate is entering a Phase 1/2 clinical trial for AL (immunoglobulin light chain) amyloidosis, multiple system atrophy and progressive supranuclear palsy.

Visit: http://www.proteotech.com
Connect with ProteoTech Inc on partnering360®

Biotech Showcase™ 2015
Pulmokine
Pulmokine
Rensselaer, New York, United States
Pulmokine is an early-clinical stage company that is developing an inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension, an orphan disease. The...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Pulmokine

Pulmokine is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 9:45 am. Room Mission I.
Pulmokine
Track: B
City: Rensselaer
State: New York
Country: United States
Ownership: PRIVATE
Pulmokine is an early-clinical stage company that is developing an inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension, an orphan disease. The company has raised $7 million in non-dilutive funding from the NHLBI to carry its program through a Phase 1 clinical trial.

Visit: http://www.pulmokine.net
Connect with Pulmokine on partnering360®

Biotech Showcase™ 2015
PxRadia Inc.
PxRadia Inc.
Savannah, Georgia, United States
PxRadia, Inc. develops a humanized monoclonal antibody 2A2 for mitigating radiation toxicity and preventing cell death.


Share this:Email this pageShare this on LinkedInShare this on Twitter

PxRadia Inc.

PxRadia Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:15 am. Room Mission I.
PxRadia Inc.
Track: B
City: Savannah
State: Georgia
Country: United States
Ownership: PRIVATE
PxRadia, Inc. develops a humanized monoclonal antibody 2A2 for mitigating radiation toxicity and preventing cell death.

Visit: http://www.pxradia.com
Connect with PxRadia Inc. on partnering360®

Biotech Showcase™ 2015
Q Therapeutics
Q Therapeutics
Salt Lake City, Utah, United States
Q Therapeutics develops neural cell therapeutics to treat diseases of the central nervous system. The company’s first product is a cell-based therapeutic intended to restore...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Q Therapeutics

Q Therapeutics is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 10:45 am. Room Mission I.
Q Therapeutics
Track: B
City: Salt Lake City
State: Utah
Country: United States
Ownership: PRIVATE
Q Therapeutics develops neural cell therapeutics to treat diseases of the central nervous system. The company’s first product is a cell-based therapeutic intended to restore or preserve normal activity of the neurons in the central nervous system. Its initial clinical target is ALS with its first IND submission expected in early 2015.

Visit: http://www.qthera.com
Connect with Q Therapeutics on partnering360®

Biotech Showcase™ 2015
QBiotics Limited
QBiotics Limited
Indooroopilly, Queensland, Australia
This clinical stage company is developing a clinical-stage NCE for the local treatment of a range of solid tumors in humans and companion animals. It is in Phase 1/2 for human...


Share this:Email this pageShare this on LinkedInShare this on Twitter

QBiotics Limited

QBiotics Limited is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 11:15 am. Room Hearst.
QBiotics Limited
Track: A
City: Indooroopilly
State: Queensland
Country: Australia
Ownership: PRIVATE
This clinical stage company is developing a clinical-stage NCE for the local treatment of a range of solid tumors in humans and companion animals. It is in Phase 1/2 for humans and Phase 2 for animal health. Its pipeline includes a wound-healing product.

Visit: http://www.qbiotics.com
Connect with QBiotics Limited on partnering360®

Biotech Showcase™ 2015
Radius Health, Inc.
Radius Health, Inc.
(NASDAQ:RDUS)
Waltham, Massachusetts, United States
Radius Health is a clinical stage company developing new therapeutics for advanced osteoporosis as well as other serious endocrine-medicated diseases including hormone...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Radius Health, Inc.

Radius Health, Inc. is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 4:00 pm. Room Powell.
Radius Health, Inc.
Track: D
City: Waltham
State: Massachusetts
Country: United States
Ownership: PUBLIC
Ticker: RDUS
Stock exchange: NASDAQ
Radius Health is a clinical stage company developing new therapeutics for advanced osteoporosis as well as other serious endocrine-medicated diseases including hormone responsive cancers. Its lead candidate is nearly completion of a Phase 3 study to evaluate its ability to reduce fracture risks in postmenopausal women with osteoporosis.

Visit: http://www.radiuspharm.com/
Connect with Radius Health, Inc. on partnering360®

Biotech Showcase™ 2015
RedHill Biopharma
RedHill Biopharma
(NASDAQ:RDHL)
Tel-Aviv, Israel
RedHill Biopharma is a late clinical stage biopharmaceutical company developing orally-administered drugs for inflammatory and gastrointestinal diseases including gastrointest...


Share this:Email this pageShare this on LinkedInShare this on Twitter

RedHill Biopharma

RedHill Biopharma is scheduled to present at Biotech Showcase™ 2015
Monday, January 12 at 2:00 pm. Room Mission II.
RedHill Biopharma
Track: C
City: Tel-Aviv
Country: Israel
Ownership: PUBLIC
Ticker: RDHL
Stock exchange: NASDAQ
RedHill Biopharma is a late clinical stage biopharmaceutical company developing orally-administered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers. Its pipeline includes three drugs that are undergoing Phase 3 studies in the US and two drugs for which marketing applications have been filed.

Visit: http://www.redhillbio.com
Connect with RedHill Biopharma on partnering360®

Biotech Showcase™ 2015
Relburn-Metabolomics, Inc.
Relburn-Metabolomics, Inc.
Westfield, New Jersey, United States
This preclinical stage company is developing drugs that treat gout by reducing the production and increasing the excretion of uric acid. This bifunctional activity has...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Relburn-Metabolomics, Inc.

Relburn-Metabolomics, Inc. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:45 am. Room Mission I.
Relburn-Metabolomics, Inc.
Track: B
City: Westfield
State: New Jersey
Country: United States
Ownership: PRIVATE
This preclinical stage company is developing drugs that treat gout by reducing the production and increasing the excretion of uric acid. This bifunctional activity has yielded clinical potency with a drug prototype. It is seeking financing to complete a pre-IND study.

Visit: http://www.relburn.com
Connect with Relburn-Metabolomics, Inc. on partnering360®

Biotech Showcase™ 2015
Relmada Therapeutics
Relmada Therapeutics
(OTCBB:RLMD)
New York, New York, United States
Relmada Therapeutics is a clinical stage specialty pharmaceutical company reformulating proven drugs as well as developing new chemical entities for the treatment of p...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Relmada Therapeutics

Relmada Therapeutics is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 11:00 am. Room Powell.
Relmada Therapeutics
Track: D
City: New York
State: New York
Country: United States
Ownership: PUBLIC
Ticker: RLMD
Stock exchange: OTCBB
Relmada Therapeutics is a clinical stage specialty pharmaceutical company reformulating proven drugs as well as developing new chemical entities for the treatment of pain and diseases of the central nervous system.

Visit: http://www.relmada.com
Connect with Relmada Therapeutics on partnering360®

Biotech Showcase™ 2015
Reneuron
Reneuron
(LSE:RENE)
Guildford, United Kingdom
ReNeuron is a clinical stage stem cell therapy company. Its primary therapeutic targets are stroke disability, critical limb ischemia and retinitis pigmentosa. Its lea...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Reneuron

Reneuron is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 4:30 pm. Room Mission II.
Reneuron
Track: C
City: Guildford
Country: United Kingdom
Ownership: PUBLIC
Ticker: RENE
Stock exchange: LSE
ReNeuron is a clinical stage stem cell therapy company. Its primary therapeutic targets are stroke disability, critical limb ischemia and retinitis pigmentosa. Its lead candidate is in Phase 2 trials, and it is funded to pursue its clinical development program through the next two years.

Visit: http://www.reneuron.com
Connect with Reneuron on partnering360®

Biotech Showcase™ 2015
RepliCel Life Sciences Inc.
RepliCel Life Sciences Inc.
(TSX-V:RP)
Vancouver, British Columbia, Canada
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits. In the next year it plans to have ...


Share this:Email this pageShare this on LinkedInShare this on Twitter

RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. is scheduled to present at Biotech Showcase™ 2015
Monday , January 12 at 2:30 pm. Room Mission II.
RepliCel Life Sciences Inc.
Track: C
City: Vancouver
State: British Columbia
Country: Canada
Ownership: PUBLIC
Ticker: RP
Stock exchange: TSX-V
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits. In the next year it plans to have clinical trials underway for chronic Achilles tendinosis, damaged and aging skin, and hair loss.

Visit: http://www.replicel.com
Connect with RepliCel Life Sciences Inc. on partnering360®

Biotech Showcase™ 2015
RestorGenex
RestorGenex
(OTCQB:RESX)
Long Grove, Illinois, United States
RestorGenex is a clinical stage specialty biopharmaceutical company focused on the dermatology, ophthalmology and women’s health markets. Its ophthalmology product t...


Share this:Email this pageShare this on LinkedInShare this on Twitter

RestorGenex

RestorGenex is scheduled to present at Biotech Showcase™ 2015
Tuesday, January 13 at 3:00 pm. Room Powell.
RestorGenex
Track: D
City: Long Grove
State: Illinois
Country: United States
Ownership: PUBLIC
Ticker: RESX
Stock exchange: OTCQB
RestorGenex is a clinical stage specialty biopharmaceutical company focused on the dermatology, ophthalmology and women’s health markets. Its ophthalmology product targets age-related macular degeneration. Its dermatology business is focused on the treatment of keloid scarring, acne, unwanted excess hair and aging skin.

Visit: http://www.restorgenex.com
Connect with RestorGenex on partnering360®

Biotech Showcase™ 2015
Resverlogix Corp.
Resverlogix Corp.
(TSX:RVX)
Calgary, Alberta, Canada
Resverlogix is developing a small molecule selective BET bromodomain inhibitor for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer...


Share this:Email this pageShare this on LinkedInShare this on Twitter

Resverlogix Corp.

Resverlogix Corp. is scheduled to present at Biotech Showcase™ 2015
Wednesday, January 14 at 10:00 am. Room Mission II.
Resverlogix Corp.
Track: C
City: Calgary
State: Alberta
Country: Canada
Ownership: PUBLIC
Ticker: RVX
Stock exchange: TSX
Resverlogix is developing a small molecule selective BET bromodomain inhibitor for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease and chronic kidney disease. It has completed Phase 2b trials.

Visit: http://www.resverlogix.com
Connect with Resverlogix Corp. on partnering360®

Biotech Showcase™ 2015
RetroSense Therapeutics
RetroSense Therapeutics
Ann Arbor, Michigan, United States
RetroSense is a preclinical company developing gene therapeutics for vision restoration in retinitis pigmentosa and dry AMD. It anticipates filing an IND in early 2015...


Share this:Email this pageShare this on LinkedInShare this on Twitter</